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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral pediatric
disorder in the United States. Pharmacotherapy is a recommended component of treatment for
ADHD. While medication treatment of ADHD is not optimized overall, minority groups
experience medication treatment disparities. The persistently lower rates of medication treatment
in minority groups may have culturally specific origins which cannot be generalized across
minorities. The purpose of this dissertation was to assess and extend knowledge regarding
medication decision making (MDM) in African American caregivers of children with ADHD. To
assess the state of the science on ADHD disparities, a review of 41 descriptive studies exploring
the relationship between ADHD diagnosis and/or treatment and race was conducted. The review
concluded that despite a trend toward reduction in ADHD diagnostic disparities over time for
African American children, medication treatment disparities persist. Next, a literature review was
conducted to synthesize what is known about the beliefs of African Americans regarding ADHD
diagnosis and treatment, and their experiences of MDM for children with ADHD. Findings from
the fourteen articles yielded a preliminary framework describing factors influencing African
American caregiver decision making. Factors included fundamental perspectives of ADHD and
cultural norms for childhood behavior, the impact of fundamental perspectives on MDM, and
ADHD as a form of social control. Subsequently, a sequential exploratory mixed method study
was conducted to identify factors associated with MDM in low-income African American
families of children with ADHD. Phase 1 comprised a case study of seven low-income African
American caregivers of children with ADHD. Phase 2 aimed at validating the qualitative
findings through secondary analysis of data from a survey of low-income African American
families of children with ADHD. Qualitative themes included child safety and volatility,
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caregiver aggravation, caregiver mental health, sole caregiver status, receipt of shared decision
making (SDM) and family centered care (FCC), and school involvement. After conducting
univariate and multivariate logistic regression analyses, previous receipt of special education
services, and receipt of FCC and SDM were independently associated with receiving a
medication for ADHD. These findings indicate that clinicians and educators can intervene to
improve health equity for children with ADHD.
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Chapter 1: Introduction
This research was conducted to explore and verify factors associated with medication
decision making (MDM) among low-income African American caregivers of children with
Attention-Deficit/Hyperactivity Disorder (ADHD). The rationale for research, gaps in the
literature, aims of the dissertation, and descriptions of the manuscripts are included in this
chapter.
Rationale for Research
Healthy People 2020 set the goal to improve mental health by ensuring access to
appropriate, quality mental health services (Office of Disease Prevention and Health Promotion
[ODPHP], 2019). Specific objectives of this goal are to increase the proportion of children with
mental health problems who receive treatment, and to reduce mental health disparities (ODPHP,
2019). Attention-deficit/hyperactivity disorder (ADHD) is one pediatric mental health diagnosis
in which both ethnic and socio-economic treatment disparities exist (Cummings et al., 2017).
Children from families whose income is less than 100% of the poverty threshold are least likely
to receive mental health treatment (ODPHP, 2019). Additionally, though African Americans
have similar rates of mental illness compared to the general population, they often receive poorer
care and lack access to culturally competent care (American Psychiatric Association [APA],
2017). To date, there is insufficient evidence to inform culturally competent care that can
facilitate health equity for African American children with ADHD.
ADHD Outcomes
ADHD is the most common neurobehavioral pediatric disorder in the United States (US).
Approximately 9.4% of US children receive the diagnosis, and 8.4% have a current diagnosis
(Danielson et al., 2018a). The symptoms of ADHD, primarily inattention, hyperactivity, and
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impulsivity, result in significant morbidity for both the child and family. Children with ADHD
are 1.3 times more likely to sustain an injury than those without, (Dalsgaard et al., 2015a) and
have more than double the risk of death (Dalsgaard et al., 2015b).
Aside from threats to safety, ADHD impacts social and academic achievement outcomes.
Compared to typical children, those with ADHD perform significantly lower in overall school
functioning including reading and standardized test scores, and have increased absenteeism and
grade retention, and lower high-school graduation rates (Barbaresi et al., 2007; Birchwood &
Daly, 2012; Wu & Gau, 2013). As children with ADHD progress to adulthood, they experience
continued underachievement. They are less likely to enroll in a 4-year college, and more likely to
work in entry level occupations, experience long-term work disability, and incur lower lifetime
earnings with greater financial dependence on family and the welfare system (Altszuler et al.,
2016; Fredriksen et al., 2014; Kuriyan et al., 2013; Voigt et al., 2017). Other related outcomes
include increased risk of unintended pregnancy, substance use disorders, criminal convictions,
and incarceration (Groenman et al., 2017; Mohr-Jensen & Steinhausen, 2016; Ostergaard et al.,
2017).
The child’s symptoms also have implications for the family. Parental and family strain
are increased, contributing to nearly double the risk for divorce (Laugesen et al, 2016; Wymbs et
al., 2008). Furthermore, parents of children with ADHD experience greater healthcare costs,
employment absenteeism and turnover, as well as decreased psychological and physical wellness
(Kleinman et al., 2009; Lovell et al., 2015).
Pharmacotherapy for ADHD
Guidelines for the treatment of ADHD recommend a combination of behavioral and
medication therapies (Wolraich et al., 2019). Behavioral therapies are interventions directed at
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changing behaviors, including contingency management, behavior therapy, and cognitive
behavior therapy (Catala-Lopez et al., 2017). However, behavioral therapies alone are inferior to
pharmacotherapy or combined behavioral and pharmacotherapy (Catala-Lopez et al., 2017; MTA
Cooperative Group, 1999). Thus, pharmacotherapy is strongly recommended as a component of
treatment for children with ADHD (Wolraich et al., 2019).
Medications for ADHD work primarily by increasing synaptic availability of dopamine
and norepinephrine (Faraone, 2018). Approved medications for ADHD are typically categorized
as stimulants or non-stimulants. Stimulants include methylphenidate and amphetamines. A
variety of medications are available for both classes, offering different preparations such as tablet
or liquid, and different formulations such as immediate release, extended release, or combined.
In children, both methylphenidate and amphetamines have demonstrated superiority in core
symptom relief over placebo based on clinician and child rating, and teacher ratings also support
methylphenidate over placebo (Cortese et al., 2018). There is an absence of head-to-head trials;
however, meta-analyses demonstrate that amphetamines may be more effective than
methylphenidate (Cortese et al., 2018; Padhila, et al., 2018). Still, methylphenidate (long- or
short-acting) remains the first-line therapy for treatment of ADHD (National Institute for Health
and Care Excellence [NICE], 2018).
Pharmacotherapy and ADHD Outcomes
There is a large body of evidence demonstrating outcomes in support of medication
treatment for ADHD. Medication therapy has a protective effect from injury in children
diagnosed with ADHD (Ruiz-Goikoetxea et al., 2018). Additionally, academic coursework
completion, classroom behavior, on-task behavior, performance on standardized achievement
tests and higher education entrance exams improve when individuals with ADHD use
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medications (Langberg & Becker, 2012; Lu et al., 2017; Prasad et al., 2013; Scheffler et al.,
2009; Shaw et al., 2012). Appropriate stimulant use can also have immediate and long-term
protective effects against substance abuse (Chang et al., 2014; Quinn et al., 2017; Shaw et al.,
2012), and improved occupational outcomes (Shaw et al., 2012). The child’s medication
treatment is associated with decreased parental report of child symptoms, and decreased parental
occupational absenteeism (Fridman et al., 2017a; MTA Cooperative Group, 1999).
Despite evidence in support of medication treatment for ADHD, only about 62% of
children with a current diagnosis of ADHD receive medication (Danielson et al., 2018a).
Reasons for caregiver hesitancy to adopt medication treatment for children with ADHD include
factors such as a non-physiologic explanation of ADHD symptoms, influence of friends and
family, influence of media and other informal information sources, negative experiences of
stigma, concerns for side effects, and fears of addiction and abuse (Gajria et al., 2014; Rashid et
al., 2018; Ross et al., 2018b; Taylor & Antshel, 2021).
ADHD Medication Treatment Disparities
While medication treatment of ADHD is not optimized overall, African American,
Hispanic, and other minority groups experience medication treatment disparities (Bax et al.,
2019; Danielson et al., 2018a). There are several points in the medication treatment process at
which children can experience disparities. The first events are provider driven and include
determination that the individual is a candidate for the drug therapy of interest followed by
writing a prescription (Raebel et al., 2013). As for receipt of a prescription, children from ethnic
minorities with a diagnosis or symptoms of ADHD are two to five times less likely to be
prescribed a medication than their White counterparts (Coker et al., 2016). Subsequent to
receiving a prescription, medication receipt becomes family and child driven, expressed as “how,
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when, and how much patients take prescribed medications, regardless of how they are
prescribed” (Alsalman & Smith, 2013, p. 118). The terms most often used to describe these
behaviors include initiation, adherence, persistence, and discontinuation. Initiation is the point at
which a patient takes the first dose of medication, adherence is the extent to which a patient’s
actual dosing corresponds to the prescribed dosing regimen, discontinuation occurs when the
patient stops taking the prescribed medication, and persistence is the length of time between
initiation and discontinuation (Vrijens et al., 2012). Concerning these child and family driven
outcomes, African American children are more likely to demonstrate low adherence with ADHD
medication regimens and gaps in treatment than white children (Faraone et al., 2007; Ji et al.,
2018; Palli et al., 2012) and are more likely to discontinue medication within a 300 day period
(Cummings et al., 2017, Ji et al., 2018).
The persistently lower rates of medication treatment in minority groups may have
culturally specific origins which cannot be generalized across minorities. For example, the role
of the male in the household is a uniquely significant factor for Hispanic children (Leslie et al.,
2007). Additionally, children from homes where Spanish is the primary language are less likely
to receive medication for ADHD than those where English is spoken (Danielson et al., 2018a).
This is likely to be a greater factor in treatment disparities for Hispanic children than African
American.
The sources for ADHD treatment disparities among African Americans are diverse and
relate to social determinants of health (SDOH) and experiences of structural and cultural racism
and discrimination. SDOH include individual culture and beliefs along with social, economic,
and environmental conditions that can influence an individual’s level of health (National
Academies of Sciences, Engineering, and Medicine [NASEM], 2019). Structural racism exists
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where laws, policies, and societal practices favor one group while oppressing another (Williams
et al., 2019). Cultural racism refers to the larger society’s ideology of inferiority and unstated
assumptions toward a minority group which manifest as stereotyping, implicit bias, and
persistent negative imagery (Williams et al., 2019). Finally, discrimination is where individuals
are treated differently resulting in inequitable access, or demonstrate altered physiologic and
health behaviors that result from the negative emotions of experiencing discrimination (Williams
et al., 2019)
The connections between SDOH or structural racism and ADHD treatment are simpler to
illustrate than cultural racism and discrimination. As evidence, children coming from affluent
households are 20% more likely to receive medication for ADHD than poor children (Pastor &
Reuben, 2005). This intersects with ethnicity, as the average income of an African American
household is less than 2/3rds that of non-Hispanic White (White), and African American families
are 2.4 times more likely to be living below poverty (Fontenot et al., 2018). Income disparities
are multifactorial, likely relating to family composition and education attainment. Based on
family composition, African American households are more likely to have a single-income, and
African American adults are less likely to obtain advanced degrees (Rostain et al., 2015; United
States Census Bureau, 2017). These inequities result from years of structures including policies
and laws that serve to oppress African Americans (NASEM, 2021).
Insurance and provider availability are important examples of SDOH driving ADHD
treatment disparities. Children without insurance are significantly less likely to receive
medication for ADHD than those with public or private insurance (Danielson et al., 2018b).
Again, this converges with ethnic disparities as 10.6% of African Americans are uninsured,
compared to 6.3% of Whites, and a staggering 26.8% of African American children living in
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poverty are uninsured (Fontenot et al. 2018). Finally, culture exerts an influence on the attitudes
of African American’s towards medical treatment of ADHD. These beliefs are founded in a deep
history of mistrust that result in underutilization of healthcare, and specifically mental health
services (Rostain et al., 2015). Additionally, only 4% of the psychology workforce is African
American (APA, 2018). Mistrust is important, as positive prior experiences with physicians is
one of the most significant factors contributing to positive attitudes toward ADHD treatment
(Taylor & Ansthel, 2019). Experiences of cultural racism and discrimination will be a focus of
this research.
Gaps in the Literature
This dissertation addresses several gaps noted in the literature. First, there is a paucity of
research on how to address ADHD treatment disparities. This is because the reasons for ADHD
treatment disparities beyond the most evident SDOHs, such as issues of access or health
insurance coverage, are poorly understood (Glasofer et al., 2021). The exploration of how
cultural racism and discrimination shape the experiences, beliefs and behaviors of African
Americans pursuing treatment for their children with ADHD is essential to ensuring ADHD
treatment equity. Secondly, the literature has treated African American children as a
homogenous group. This approach fails to recognize how the intersection of SDOHs, like race
and socioeconomic status together, converge to impact outcomes in ADHD treatment. Moreover,
understanding differences between individuals of a similar background who do and do not select
medication treatment for their children with ADHD will yield information on barriers and
facilitators to MDM. Finally, the literature largely treats MDM as a distinct event with a binary
outcome- a child is either on or not on medication for ADHD. Little attention has been paid to
the dynamic process of MDM, whereby a prescription is written with a number of decisions that
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must follow and may be revisited as a child’s ADHD medication treatment status fluctuates over
time. Qualitative research is needed to explore MDM as a process in order to measure and
promote engagement and family centered care throughout treatment, rather than simply measure
treatment initiation. A focus on MDM as a process transcends the traditional view of ADHD
medication treatment as a finish line to consideration of ADHD treatment quality. Long-term (>
2 years) and consistent treatment of ADHD reduces the negative impact of ADHD on life
functioning (Shaw et al., 2012). Research is needed to better quantify disparities in ADHD
treatment adherence and persistence, and test interventions aimed at addressing these disparities
and promoting improved treatment quality and duration in minority children.
Aim of the Dissertation Project
The aim of this dissertation was to assess and extend knowledge regarding MDM in
African American caregivers of children with ADHD. This aim has three components: a
literature review establishing disparities in ADHD medication treatment for African American
children with ADHD; a literature review identifying gaps in understanding MDM in African
American caregivers of children with ADHD; and the conduct of a mixed-method study to
explore and validate factors associated with MDM in low-income African American families of
children with ADHD. The implications of identifying factors associated with MDM in this
population include providing the knowledge necessary for interventions to achieve health equity
for African American children with ADHD.
Manuscript Selection
This dissertation is comprised of three manuscripts focused on ADHD disparities and
MDM in low-income African American caregivers of children with ADHD. The first manuscript
offers an in-depth review of literature and state of the science on ADHD diagnostic and
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treatment disparities. The second manuscript provides a review and synthesis of existing
literature on MDM in low-income African American caregivers of children with ADHD. The
third manuscript provides a data-based report of the dissertation study that explores experiences
of MDM in low-income African American caregivers of ADHD and tests associations resulting
from the exploratory inquiry. Therefore, the first manuscripts establish the existence of persistent
ADHD treatment disparities in African American children, the second describes current gaps in
understanding these disparities, and the final manuscript describes an investigation that addresses
the identified gaps.
Manuscript 1. The first manuscript is a literature review of ADHD diagnosis and
treatment disparities in African American children with ADHD. Though research describing
ADHD disparities has been ongoing since the 1990s, no published review of the relevant
research was identified. A total of 41 studies were included in this review. Of these studies, 38
were cross-sectional, and three were longitudinal in design. The studies were descriptive in
nature, examining the relationship between ADHD diagnosis and/or treatment and various
demographic and socio-economic variables. The review concluded that despite a trend toward
reduction in ADHD diagnostic disparities over time, medication treatment disparities persist.
Identifying the inequity in treatment for African American children with ADHD demands further
exploration and development of strategies to address disparities.
Manuscript 2. The second manuscript focuses on synthesizing what is known about the
beliefs of African Americans regarding the diagnosis and treatment of ADHD, and experiences
of MDM in African American caregivers of children with ADHD. Only articles with a primary
focus on African American caregivers’ perspectives of ADHD medication treatment in children
were retained for analysis. The final fourteen articles included seven observational studies, four
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qualitative studies, and three mixed methods studies. The manuscript provides a preliminary
framework describing known factors influencing African American caregiver decision making.
These include fundamental perspectives of ADHD and cultural norms for childhood behavior,
the impact of fundamental perspectives on MDM, and ADHD as a form of social control.
Critical gaps in understanding these MDM experiences in African American caregivers were
identified, mainly understanding MDM as a process, and how experiences contribute to decision
making. The manuscripts provide evidence-based recommendations for practice, specifically the
provision of family centered care, and approaching medication treatment as an ongoing process.
Finally, research priorities include development of culturally sensitive ADHD diagnostic tools,
further exploration of the relationship between internalized racism and ADHD MDM, and
interventions to overcome mistrust in healthcare providers among African Americans caring for
children with ADHD.
Manuscript 3. The final manuscript is an exploratory sequential mixed method study of
MDM in low-income African American children with ADHD and their caregivers. Phase 1
utilized qualitative methods to conduct a case-study identifying factors associated with a MDM
in a sample of low-income African American caregivers of children with ADHD. Phase 2 sought
to validate these findings through secondary data analysis of related demographic, health, social,
and educational measures in a sample of African American children with ADHD using data from
the National Survey of Children’s Health (NSCH). The NSCH is a mail- or internet-based survey
conducted by the U.S. Census Bureau within the U.S. Department of Health and Human Services
covering the 50 states and the District of Columbia. The survey collects information on key
indicators of health and well-being for children ages 0-17. Data from the 2016-2019 surveys
were utilized. The qualitative themes included child safety and volatility, caregiver aggravation,
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caregiver mental health, sole caregiver status, receipt of shared decision making (SDM) and
family centered care (FCC), and school involvement. After conducting univariate and
multivariate logistic regression analyses, previous receipt of special education services, and
receipt of FCC and SDM were independently associated with receiving a medication for ADHD.
Findings from this study offer guidance to clinicians and educators interfacing with low-income
African American families of children with ADHD, and establish directions for future research
in working to achieve health equity for children with ADHD.

11

Chapter 2: Manuscript 1
Diagnostic and medication treatment disparities in African American children with ADHD: A
literature review
The first manuscript is a review of the literature on diagnostic and medication treatment
disparities in African American children with ADHD. This review includes 41 observational
studies exploring the relationship between ADHD diagnosis and/or treatment and race. The
majority of studies reviewed concluded that African American children were less likely than
White children to be diagnosed with ADHD, and African American children with ADHD were
less likely to receive a medication. When looking at trends, diagnostic disparities improved over
time while medication treatment disparities persisted. The findings indicate that despite more
than twenty years of research describing ADHD treatment disparities, interventions have been
insufficient to assure health equity for African American children with ADHD.
In September, 2021 this manuscript was published online in the Journal of Racial and
Ethnic Health Disparities, the leading peer-reviewed journal dedicated to examining and
eliminating racial and ethnic health disparities (Springer, 2021). Copyright permission was
obtained from the publisher to include this manuscript in this dissertation (Appendix A). Written
permission was obtained from the coauthor to include this manuscript in the dissertation
(Appendix B).

Glasofer, A. & Dingley, C. Diagnostic and medication treatment disparities in African
American children with ADHD: A literature review. Journal of Racial and Ethnic Health
Disparities. September 14, 2021. DOI: 10.1007/s40615-021-01142-0. Springer Nature.
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Abstract
Background: Despite a national focus on achieving health equity, limited attention has been paid
to behavioral and pediatric health disparities. As the most common pediatric neurobehavioral
disorder, Attention-Deficit/Hyperactivity Disorder (ADHD) provides an opportunity to assess the
status of pediatric behavior health disparities. The purpose of this literature review is to provide a
synthesis of existing research on ADHD diagnostic and treatment disparities between African
American and White children. Methods: Studies were systematically identified through searches
in Pubmed, CINAHL, and APA PsycInfo using the terms Attention-deficit/hyperactivity
disorder, disparity, race, ethnicity, diagnosis, medication, and treatment. Summary calculations
were conducted to report the proportions of studies with statistically significant differences in
ADHD diagnosis and treatment between White and African American children, and to describe
trends in disparities over time. Results: Forty-one studies were included in this review. The
majority of studies identified significant disparities in ADHD diagnosis and medication
treatment between African American and White children. While diagnostic disparities show a
trend toward reduction over time, a similar trend was not observed in medication treatment
disparities. This synthesis provides a critique of the existing literature, and recommendations for
practice and future research.
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Introduction
Racial and ethnic health disparities have received considerable attention since the turn of
the 21st century (Agency for Healthcare Research and Quality [AHRQ], 2003). While Healthy
People 2000 initially aimed to reduce health disparities, Healthy People 2020 expanded the goal
to “achieve health equity, eliminate disparities, and improve the health of all groups”
(HealthyPeople.gov, 2021). As Meyers et al. (2021) wrote, “a lack of health equity underlies
these disparities and continues to result in unconscionable differences in patient outcomes” (para.
2). However, limited attention has been paid to behavioral and pediatric health disparities
(American Psychological Association [APA], 2017; Flores et al., 2010). Accordingly, the
American Academy of Pediatrics (AAP) prioritized advancing both the equity agenda and mental
health care for children in 2021 (Hegland, 2021). Similarly, the National Institute of Mental
Health’s (NIMH) most recent strategic plan for research includes addressing mental health equity
(National Institute for Mental Health [NIMH], 2020). The Institute of Medicine (IOM) (2003)
recommended research should explore sources of racial and ethnic disparities, and monitor
progress toward elimination of these disparities. Perhaps the best lens through which to view the
status of disparity research at the intersection of pediatric and behavior health is attention-deficit
hyperactivity disorder (ADHD).
ADHD is the most common neurobehavioral pediatric disorder in the United States (US).
Approximately 9.4% of US children receive the diagnosis in their lifetime, and 8.4% report a
current diagnosis (Danielson et al., 2018a). The symptoms of ADHD, primarily inattention,
hyperactivity, and impulsivity, result in significant morbidity for both the child and family. Shaw
and colleagues (2012) reviewed 351 studies, grouping the outcomes of ADHD into categories
including academic, antisocial behavior, driving, substance abuse, occupation, service use,
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obesity, self-esteem, and social function. They found that 74%, or 244 of these studies reported
poorer outcomes in untreated participants with ADHD compared to non-ADHD participants
(Shaw et al., 2012). Specifically, individuals with ADHD have more than double the risk of
death than those without (Dalsgaard et al., 2015a). Additionally, children with ADHD are two
times more likely to sustain an injury (Amiri et al., 2017). Excess mortality and injury rates
among individuals with ADHD are driven by accidents and substance abuse (Dalsgaard et al.,
2015b).
Regarding academic performance, children with ADHD perform significantly lower in
overall school functioning than typical children, including reading and standardized test scores
(Barbaresi et al., 2007; Birchwood & Daley, 2012; Wu & Gau, 2013). Among children with
ADHD, the odds are increased for failure to complete high school (OR = 3.7), expulsion (OR =
3.9), grade retention (OR = 3.64), and suspension (OR = 6.31) (Erskine et al., 2016). As children
with ADHD progress to adulthood, they experience continued underachievement. Individuals
without ADHD are more likely to enroll in a 4-year college (OR = 6.47), while those with
ADHD are more likely to work in entry level occupations, experience long-term work disability,
be fired (OR = 3.92), experience unemployment (OR = 1.97) and incur lower lifetime earnings
with greater financial dependence on family and the welfare system (Altszuler et al., 2016;
Fredriksen et al., 2014; Kuriyan et al., 2013; Voigt et al., 2017).
Social outcomes are impacted as well. The prevalence of ADHD among detained
children is estimated to be 41.1%, a five-fold increase compared to the general population
Baggio et al., 2018). There is a two-fold risk for arrest, and three-fold for conviction and
incarceration (Mohr-Jensen & Steinhausen, 2016). Childhood ADHD is associated with future
substance abuse (Groenman et al., 2017). There are increased odds for substance use disorder
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(OR = 1.73), illicit drug use (OR = 2.24) and illicit drug use disorder (OR = 2.57), alcohol abuse
(OR = 1.29) and alcohol use disorder (OR = 1.60), and tobacco dependence (OR = 2.41)
(Erskine et al., 2016). Finally, compared to others, children with ADHD are significantly more
likely to become parents by the age of 16, with nearly a three-fold risk of early pregnancy
(Erskine et al., 2016; Ostergaard et al., 2017).
The child’s symptoms also have implications for the family. Parental and family strain
are increased, including negative experiences of guilt, blame, stigmatization, and exhaustion
(Laugesen et al., 2016). This impacts health, psychological, marital, and occupational
functioning (Corcoran et al., 2017). Caregivers of young children with ADHD are nearly twice
as likely to become divorced (Wymbs et al., 2008). Employed caregivers of children with ADHD
have significantly greater healthcare costs, health related absence days, and termination rates
than those of children without ADHD (Kleinman et al., 2009). The economic burden also
includes costs of accidents and injuries, criminality, healthcare including prescriptions and
appointments, replacement of lost items, and prolonged financial dependence (Usami, 2016).
Furthermore, parents of children with ADHD experience decreased psychological and physical
wellness (Lovell et al., 2015).
Guidelines for the treatment of ADHD recommend a combination of behavioral and
medication therapies (Wolraich et al., 2019). Behavioral therapies are interventions directed at
changing behaviors, including contingency management, behavior therapy, and cognitive
behavior therapy (Catala-Lopez et al., 2017). However, behavioral therapies alone are inferior to
pharmacotherapy or combined behavioral and pharmacotherapy (Catala-Lopez et al., 2017; MTA
Cooperative Group, 1999). Thus, pharmacotherapy is strongly recommended as a component of
treatment for children with ADHD (Wolraich et al., 2019). Medications for ADHD work
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primarily by increasing synaptic availability of dopamine and norepinephrine (Faraone et al.,
2007). Approved medications for ADHD are typically categorized as stimulants or nonstimulants. Stimulants include methylphenidate and amphetamines (Dupar & Dodson, 2018). A
variety of medications are available for both classes, offering different preparations such as
tablet, capsule, or liquid, and different formulations such as immediate release, extended release,
or combined (Dupar & Dodson, 2018). While treatment recommendations for ADHD include
both behavior and pharmacotherapy, this review is focused on medication treatment. Thus, the
term treatment will further refer specifically to medication treatment.
There is a large body of evidence demonstrating positive outcomes to support
pharmacotherapy for ADHD. In their review, Shaw et al. (2010) found that across all categories
of studied outcomes, 72% reported benefits related to pharmacotherapy. With regard to safety,
medication therapy has a protective effect from injury in children with ADHD (Ruiz-Goikoetxea
et al., 2018). Pharmacological treatment of childhood ADHD corresponds to a 31.5-43.5%
reduction in injuries, a 28.2-45.7% reduction in emergency department visits, and a significant
reduction in overall hospital contact (Dalsgaard et al., 2015a; Dalsgaard et al., 2014). There is a
38-42% reduction in risk of motor vehicle collision with medication use (Chang et al., 2017).
Likewise, pharmacotherapy for ADHD can benefit academic outcomes. Academic coursework
completion, classroom behavior, on-task behavior, grade point average, performance on
standardized achievement tests and higher education entrance exams improve when individuals
with ADHD use medications (Keilow et al., 2018; Langberg & Becker, 2012; Lu et al., 2017;
Prasad et al., 2013; Scheffler et al., 2009; Shaw et al., 2012).
Treatment is associated with improved social and family outcomes as well. The odds of
substance abuse during treatment for ADHD, and for two- to three-years following treatment, are
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significantly reduced with stimulant use (Chang et al., 2014; Goksoyr & Nottestad, 2008; Quinn
et al., 2017). Pharmacotherapy also decreases risk for criminality, including police interaction
and arrest (Dalsgaard et al., 2014; Goksoyr & Nottestad, 2008). Regarding family function, the
majority of parents with children receiving medication for their ADHD were satisfied with
symptom control, which was subsequently highly correlated with medication satisfaction
(Fridman et al., 2017a). Parental employment absenteeism is reduced when the child is
medicated, as is family strain (Fridman et al., 2017b; Silva et al., 2015; Gajria et al., 2014).
Given the evidence in support of pharmacotherapy for ADHD, it follows that a
significant body of research has been dedicated to describing the prevalence of ADHD diagnosis,
treatment, and patient experiences with treatment. Gajria et al. (2014) conducted a review of
medication taking experiences for individuals with ADHD, including 41 studies with reasons for
ADHD medication discontinuation, switching, and nonadherence. Rashid et al. (2018b) followed
with an updated review of 30 additional studies, and related research continues (Flood et al.,
2019; Ross et al., 2018; Taylor & Antshel, 2021). However, no review examined the literature on
ADHD prevalence or treatment related to ethnic and racial disparities. This is significant as such
a review would allow for a synthesis of the state of the science regarding disparities in ADHD
diagnosis and treatment. Moreover, a review could provide necessary guidance for clinical
practice and future research. Finally, a review may serve as a proxy for monitoring progress
toward eliminating pediatric behavioral health disparities.
ADHD medication and treatment disparities exist across racial and ethnic subgroups;
however, causes for disparities vary between races (Bax et al., 2019). For example, Latino
children are significantly less likely to be diagnosed with or treated for ADHD than non-Latino
(Danielson et al., 2018a). Children from homes where Spanish is the primary language are also
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significantly less likely to be diagnosed with or treated for ADHD (Danielson et al., 2018a).
Thus, it may be that language spoken at home is a driver of disparities for Latino children,
though this would be less significant for African American children. The sources for ADHD
treatment disparities among African Americans are diverse (Rostain et al., 2015). Attitudes of
African American’s towards medical treatment of ADHD symptoms are founded in a deep
history of mistrust that result in underutilization of healthcare, and specifically mental health
services (Rostain et al., 2015). Additionally, only 4% of the psychology workforce is African
American (APA, 2018). Mistrust is important, as positive prior experiences with physicians is
one of the most significant factors contributing to positive attitudes toward ADHD treatment
(Taylor & Antshel, 2021). Cultural and historical factors render African American children
vulnerable to ADHD diagnostic and treatment disparities unique from other minority groups
(Bax et al., 2019). Thus, the purpose of this literature review is to provide a synthesis of existing
research on ADHD diagnostic and treatment disparities between African American and White
children. The objectives of this review are threefold: (a) to summarize the evidence describing
diagnostic and medication treatment disparities between African American and White children;
(b) to explore potential causes for variations in findings; and (c) to view the reporting of
disparities over time as a report on the progress of eliminating ADHD disparities.
Methods
Study Search, Retrieval, and Selection
Studies were systematically identified through searches in Pubmed, CINAHL, and APA
PsycInfo. Relevant articles referenced in studies identified through database searches meeting the
inclusion criteria were also reviewed. Search terms included Attention-deficit/hyperactivity
disorder, disparity, race, ethnicity, diagnosis, medication, and treatment. Database searches were
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limited to research published prior to March, 2021. Studies were included or excluded based on
the following criteria:
Inclusion Criteria:
1. Published in English
2. Published in a peer-reviewed journal
3. Participants limited to children as defined by each publication.
4. Quantitatively reported ADHD diagnostic or medication treatment disparities
between White and African American children and included a measure of statistical
significance
5. Could be retrieved through university library services
Exclusion Criteria:
1. Published in a foreign language
2. Non-peer reviewed papers
3. Qualitative research or secondary sources
4. Epidemiological reports racial disparities in ADHD diagnosis or treatment without a
measure of statistical significance
The initial search, based on the stated search terms, yielded a significant number of articles
(3563) and was reduced to 1466 once duplicates were removed, including duplicate descriptions
that were clearly the same study. Those records were then further screened for relevance based
on the inclusion and exclusion criteria, resulting in 77 articles. After a more detailed review of
the 77 articles, 36 were excluded as they did not include sufficient race comparisons, lacked a
focus on ADHD prevalence/treatment, combined ADHD with other diagnoses so that it was
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indistinguishable, and lacked a measure of statistical significance. The final composite of articles
(41) was included in this literature synthesis. (Figure 1).
Data Extraction and Summary Measures
The main findings and outcomes were compared across studies. Summary calculations were
conducted to report the proportions of studies with statistically significant differences in ADHD
diagnosis and treatment between White and African American children. The authors conducted
group discussions to draw inferences from the data regarding the overall results of the synthesis,
trends that could possibly explain variations in individual study findings, and trends in disparities
over time. Discussion and review of the primary sources continued until consensus was reached
and the findings of the review were confirmed. Data extracted from each study included sample
and setting, measure of ADHD diagnosis and medication treatment, difference in diagnosis or
medication treatment between White and African American subjects. Odds ratios (OR), adjusted
odds ratios (AOR), prevalence ratios (PR), and p values are reported to summarize the
association and significance between race, and diagnosis or treatment.
Results
A total of 41 studies were included in this review (Figure 1). Of these studies, 38 were
cross-sectional (Table 1), and three were longitudinal in design. The studies were descriptive in
nature, examining the relationship between ADHD diagnosis and/or treatment and various
demographic and socio-economic variables. For the purposes of this review, independent
variable data extraction was limited to race (African American and White). Sample sizes ranged
from 242 children to 304,951, with some studies providing annualized and population estimates.
Participants ranged in age from 0-22, with 18 (44%) studies limited to children between the ages
of 6 and 18. Most studies (24, 59%) included nationally representative samples, while six (15%)
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represented single or multi-state level data and 11 (26%) drew local or regional samples. Among
the studies reporting racial breakdown of the sample (n = 32), thirteen (41%) approximated
similar proportions of African American and White children compared to 2019 national data
(Annie E. Casey foundation, 2019). African Americans were overrepresented by at least 10% in
eleven (34%) samples and underrepresented by at least 5% in two (6%) samples. White children
were overrepresented by at least 20% in 6 (19%) samples and underrepresented by at least 20%
in 4 (13%) samples.

Figure 1
Search Flow Diagram

22

Table 1
Diagnostic and Medication Disparities between White and African American Children with ADHD
Source

Sample/ Setting

Measures

Anderson et al.
(2015)

Children age 2-21
N = 1,778
60.7% White, 18.4%
African American, 20.9%
Hispanic
Nationally representative
data from the Medical
Expenditure Panel
Survey (MEPS) from
2008-2011.
Children age 5-17
N = 50,463
28.5% White, 4.5% African
American, 3.1%
Hispanic, 1.7% Other,
62.3% Unknown
Primary care clinics from a
system serving eastern
Wisconsin from 20042006
Children age 4-12
N = 1,068 children
51.3% White, 28.6%
African American, 10.4%
Hispanic, 9.6% Other
One school district in South
Carolina and 6 school
districts in Oklahoma

Parent report of child with
outpatient visit for
ADHD
Parent report of stimulant
or alpha-2 agonist for
child

Baumgardner
et al. (2010)
[2005]$

Bax et al.
(2019)

Prevalence Findings

No significant association
between medication
receipt and
race/ethnicity

ICD-9 Diagnosis of
ADHD

African American children
were less likely than
White children to be
diagnosed with ADHD
(10.6 vs. 17.3%)***
(OR 0.55)

Vanderbilt ADHD
Diagnostic Teacher
Rating Scale
Parent report of child with
ADHD diagnosis or
medication
Parent interview

African American children
were less likely than
White children to be
diagnosed with ADHD
(OR 0.47)*.
No significant differences
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Medications Findings

African American children
were less likely to be
receiving a medication
for ADHD (OR 0.43)*

Source

Sample/ Setting

Measures

Prevalence Findings

Medications Findings

in ADHD prevalence
between races based on
teacher ratings.
Coker et al.
(2009)

Children in 5th grade
N = 5,147
3 urban areas in the US
Baseline data from
longitudinal study

Parental report of child
with ADHD symptoms
based on Diagnostic
Interview for Children
Predictive Scales
Parent report of child
mental health care
utilization

Coker et al.
(2016)
[2005$#, 2007#,
2010$#]

Children in 5th grade
N = 4,297
22.1% White, 29.1%
African American, 44.4%
Latino, 4.4% Other
3 timepoints (5th, 7th, and
10th grade) from 3 urban
areas in the US.

Collins &
Clearly (2016)

Children age 5-17
N = 190,409

Parent report of child with
ADHD symptoms based
on Diagnostic Interview
for Children Predictive
Scales
Parental report of child
with physician diagnosis
of ADHD.
Parent report of child
taking medication for
overactivity,
hyperactivity, or
difficulty paying
attention.
Parent report of child with
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African American parents
were more likely to
report symptoms of
ADHD for their children
than White parents (14%
vs. 10%) (OR 1.4)**
African American children
with ADHD symptoms
were less likely to use
mental health care than
White children (49% vs.
20%) (OR 0.3)***
African American parents
more likely to report
child with ADHD
symptoms at all time
points (5th grade 12% vs.
7%, 7th grade 11% vs.
6%, 10th grade 13% vs.
9%).
African American children
less likely to be
diagnosed with ADHD
in 5th grade (OR
0.54)*** and 10th grade
(OR 0.46)***
African American children

African American children
with a diagnosis/symptoms
of ADHD were less likely
than White children to
receive medication for
ADHD at all time points
(5th grade AOR 0.43***,
7th grade AOR .41***, 10th
grade AOR 0.44***)

Source
[2011]$

Cuffe, et al.
(2005)

Cummings, et
al. (2017)

Sample/ Setting

Measures

58.2% White, 14.2%
physician diagnosis of
African American, 18.9%
ADHD.
Hispanic, 8.3%f other
Nationally representative
data from National
Surveys of Children’s
Health (NSCH) from 3
years (2003, 2007, 2011)
Children age 4-17
Parent report of child with
N = 10,255
ADHD symptoms based
64.5% White, 15.1%
on the Strengths and
African American, 16%
Difficulties
Hispanic, 4.5% other
Questionnaire
Nationally representative
data from the 2001
National Health Interview
Survey (NHIS)

Nationally representative
sample of children age 612
N = 172,322
47.9% White, 30.9%
African American, 14.4%
Hispanic, 1% Other,
5.9% Unknown
Medicaid data from 2008
2011
Danielson et al. Children age 2-17
(2018a)
N = 45,736
77.6% White, 6.2% African
[2016]$#
American, 16.3% Other

Prevalence Findings
were less likely than
White children to be
diagnosed with ADHD
(AOR 0.62)*

African American parents
were more likely than
White parents to report
clinically significant
symptoms of ADHD,
though the difference
was not statistically
significant (5.65% vs.
4.33%)

ICD-9-CM diagnosis of
ADHD on 2 distinct
visits
Prescription for ADHD
medication filled
Medication
discontinuationmedication fills for <210
of 300 days
Parent report of child with
healthcare provider
current and lifetime
diagnosis of ADHD
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Medications Findings

African American
children were more
likely to discontinue
medication compared to
White children (72.7%
vs. 49.8%)***

In weighted prevalence
estimate, African
American children were
more likely than White

No statistically significant
difference in a
medication for ADHD
between African

Source

Danielson, et
al. (2018b)
[2014]#

Davis et al.
(2020)
[2017]$

Davis et al.
(2021)
[2017]$#

Sample/ Setting

Measures

Prevalence Findings

Weighted national
prevalence based on data
from 2016 NSCH

Parent report of child
currently taking
medication for ADHD

Children aged 4-17
N = 2,495
71.7% White, 16.2%
African American, 12.1%
Other
Data from 2011-2012
National Survey of the
Diagnosis and Treatment
of ADHD and Tourette
Syndrome study

Parental report of child
with physician diagnosis
of ADHD.
Parental report of child’s
lifetime and current
medication treatment for
ADHD

Children age 2-5
N = 2,397
76.1% White, 10.5%
African American, 3%
Hispanic, 10.3 other or
missing
Kentucky Medicaid claims
from 2017

ICD-10 diagnosis of
African American children
ADHD
were less likely to be
National drug code (NDC)
diagnosed with ADHD
for treatment with alphathan White children (OR
2 agonist or stimulant
0.76)***

Children age 6-17
N = 304,951
76% White, 14.2% African

ICD-10 diagnosis of
ADHD
NDC for treatment with
stimulant
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children to have a
current (PR 1.27)* or
lifetime (PR 1.27)*
diagnosis of ADHD

After accounting for
confounding variables,
African American
children were less likely

Medications Findings
American and White
children (PR 0.98)

No significant difference
in percent of children
currently receiving
medication for ADHD
(69.2% of White, 61.6 of
African American
children) (OR .89)
More White children had
received medication in
their lifetime compared
to African American
children (93.3 vs.
83.3%)* (OR .89)
There was no difference
in receipt of stimulant
medication (OR .8), or
combination of stimulant
plus alpha-2 agonist (OR
.71)
African American
children were less likely
to receive an alpha-2
agonist alone (OR
0.36)***
African American
children were less likely
to receive a stimulant

Source

Froelich, et al.
(2007)
[2003]$#

Hudson et al.
(2007)
[2001]$#

Sample/ Setting
American, 6.7%
Hispanic, 3.1% other
Kentucky Medicaid claims
from 2017
Children age 8-15
N = 3,082
29.4% White, 33.3%
African American, 30.1%
Mexican American, 7.2%
Other
National Health and
Nutrition Examination
Survey 2001-2004

Children aged 5-17
N = 19,115 person-years
48.2% White, 18.8%
African American, 32.9%
Hispanic
Nationally representative
data from MEPS from
2000-2002

Measures

Prevalence Findings
to be diagnosed with
ADHD than White
children (AOR 0.71)*

DSM-IV ADHD diagnosis
Parent report of child with
ADHD symptoms and
medication use based on
Diagnostic Interview
Schedule for ChildrenIV (DISC-IV)

Parent report of child with
ADHD diagnosis
Parent report of
medication
purchases for child
Pharmacy component of
MEPS including NCD
data.
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Medications Findings
than White children
(AOR 0.68)*

African American children African American
were less likely than
children were less likely
White children to be
to receive ADHD
diagnosed with ADHD
medication treatment in
in the past year (AOR
the past year (OR 0.7)*
0.7)*, and less likely to
There was no significant
be diagnosed with
difference between
inattentive type (AOR
groups in taking
0.4)*, or hyperactivemedication for most of
impulsive type (AOR
the past year.
0.6)*. No statistically
significant difference
between groups in
diagnosis with ADHD
combined type (OR 1.6).
Overall African American
children were less likely
than White children to
be diagnosed with
ADHD (OR 0.8)
African American children African American
were less likely than
children were less likely
White children to be
than White children to
diagnosed with ADHD
receive stimulants (2.8%
(2.8% vs. 5.8%)* (OR
vs. 5.1%)* (OR .55)
0.48)

Source

Sample/ Setting

Ji et al. (2018)

Children age 6-12
N = 102,669
47.8% White, 32.1%
African American, 13.7%
Hispanic, 6.5%
other/unknown
Medicaid claims from 9
states from 2008 to 2010

Johansen et al.
(2015)
[2008]#

Jonas et al.
(2013)
[2008]#

KamimuraNishimura et
al. (2019)

Measures

Medicaid records with
ICD-9-CM diagnosis of
ADHD on 2 distinct
dates
Prescription fill for ADHD
medication
Patterns of medication
treatment: continuous =
fills for at least 210
medication days/300,
early termination, or
medication gaps of at
least 14 days with
reinitiation
Children age 12-17
Participant report of
N = 11,343
amphetamine,
58.2% White, 15.1%,
methylphenidate or
African American, 18.9%
atomoxetine prescription
Hispanic, 8.5% Other
followed by pharmacy
MEPS data from 2003-2012
confirmation
Children age 12-19
Participant report of
Population based estimate
medication used in
Nationally representative
previous month
data from National
classified as treatment
Health and Nutrition
for ADHD by NDC
Examination Survey data
from 2005-2010
Children in grades 1-5
ADHD medication
N = 577 patients
prescribed within one
62% White, 38% nonyear of ADHD-related
White
contact
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Prevalence Findings

Medications Findings
Compared to White
children, African
American were less
likely to receive
continuous medication
treatment (27% vs.
49.6%)***, and more
likely to experience
early termination (14.6%
vs. 11.6%)***, 2 gaps in
treatment (22.3%
vs.15.6%)*** and 3 or
more gaps in treatment
(32% vs. 18.9%)***
African American
children were less likely
than White children to
be taking a medication
for ADHD (OR
0.53)***
African American
children were less likely
than White children to
receive medication for
ADHD (2.2% vs 4%)*
(OR .55)
Child race was not
significantly associated
with ADHD medication
prescription

Source

Karnik et al.
(2010)
[1999]$

LeFever, et al.
(1999)
[1996]#

Sample/ Setting

Measures

Prevalence Findings

Children referred for
ADHD
symptoms from 50
pediatric practices in
central and northern Ohio
Youths age 13-22
N = 790
17% White, 28% African
American, 47% Hispanic,
8% other
Juveniles admitted to
California Division of
Juvenile Justice October
1997 – June 1999

Diagnostic Interview for
Children and Adolescents
(DICA)

No statistically significant
difference in ADHD
between African
American and White
boys (6% vs. 13%) (OR
0.46)
African American girls
were significantly less
likely than White girls to
be diagnosed with
ADHD (10% vs.
34%)** (OR 0.29)
Overall African American
children were less likely
than White children to
be diagnosed with
ADHD (OR 0.36)

Children in grades 2-5
N = 27,910
66.2% White, 33.8%
African American
Children enrolled in two
public school districts in
southeastern Virginia

ADHD medication
administration by school
nurse during school
hours
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Medications Findings

African American
children were less likely
than White children to
receive medication for
ADHD (OR 0.450.48***

Source

Sample/ Setting

Measures

Prevalence Findings

Medications Findings

Lingineni et al.
(2012)

Children age 5-17
N = 68,634
56.8% White, 14.9%
African American, 19.8%
Hispanic, 8.5% Other
Weighted national
prevalence based on data
from NSCH 2007-2008

Parent report of child with
healthcare provider
diagnosis of ADHD
Parent report of child
taking medication for
ADHD

African American children
were less likely than
White children to be
diagnosed with ADHD
(OR 0.72)*

Lipkin et al.
(2005)

Children age 4-19
N = 242
44.6 White, 52.9% African
American, 2.5% other
Children from an urban
referral center on a stable
dose of stimulant for at
least 6 months

Medical record review for
prescription information

African American
children with ADHD
were less likely to
receive a medication for
ADHD than White
children but the
difference was not
statistically significant
(OR 0.74)
African American
children with Medicaid
received significantly
lower stimulant doses
than non-African
American children with
Medicaid (30mg/day vs.
39.9mg/day)***
African American
children with private
insurance received
significantly higher
stimulant doses than
non-African American
children with private
insurance (35.6mg/day
vs. 30.1mg/day)**

Merikangas et
al. (2011)

Children age 13-18
N = 10,148
65.6% White, 15.1%
African American, 14.4%
Hispanic, 4.9% other
Nationally representative

Interview conducted using
World Health
Organization Composite
International Diagnostic
Interview 3.0, based on

[2008]$#

[2003]$
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African American children
were less likely than
White children to be
diagnosed with ADHD
(AOR 0.58)*

Source

Morgan et al.
(2014)
[2006]$#

Morgan et al.
(2013)
[2003]$#

Palli et al.
(2012)

Sample/ Setting
data from National
Comorbidity SurveyAdolescent
Children age 5
N = 6,550
53.7% White, 13.9%
African American, 25.1%
Hispanic, 7.2% Other
Nationally representative
data from the Early
Childhood Longitudinal
Study- Birth Cohort

Children followed from
kindergarten to 8th grade
N = 17,100
57.3% White, 15.7%
African American, 19.3%
Hispanic, 7.6% Other
Nationally representative
data from the Early
Childhood Longitudinal
Study- Kindergarten
cohort
Children age 6-19
N = 46,135
Medicaid claims data from
4
states for 2003-2005

Measures

Prevalence Findings

Medications Findings

African American children
were less likely than
otherwise similar white
children to receive
ADHD diagnosis (OR
0.30**-0.72 depending
on model covariates).
No differences between
teacher rating of
behaviors displayed
across races.
African American children
were less likely to be
diagnosed with ADHD
(OR 0.31-0.64
depending on
model)***.

African American
children were less likely
to be taking stimulants
than White children, but
the difference was not
statistically significant
(30% vs. 40%) (OR
0.75)

DSM-IV criteria for
ADHD
Parent report of child with
physician diagnosis of
ADHD
Parent report of child
taking medication for
ADHD

Parental report of child
with diagnosis of ADD,
ADHD, or hyperactivity
Parental report of child
taking medication for
ADD or ADHD or
hyperactivity

At least one visit with ICD
9 Clinical Modification
(ICD-9 CM) code for
ADHD
Initiation of stimulant
therapy during study
period
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African American
children were less likely
than White children to
receive a medication for
ADHD (OR 0.35)***

Persistence across 3 types
of stimulants was
significantly lower
among African
American children
compared to White

Source

Pastor &
Reuben. (2005)
[1999]$

Rowland et al.
(2002)

Sample/ Setting

Children age 6-11
N = 20,401
55.3% White, 17.5%
African American, 27.2%
Hispanic
National Health Interview
Survey 1997-2001

Children in grades 1-5
N = 6,099
72.7% White, 19.8%

Measures
Persistence = consecutive
stimulant refills without
a 30 day gap in
treatment
Analyzed by stimulant
action: short-acting
stimulant (SAS);
intermediate-acting
stimulant (IAS); longacting stimulant (LAS)
Parental report of
diagnosis
of ADHD or ADD with
or without a learning
disability (LD)

Parent report of child with
ADHD diagnosis
Parent report of child

[1998]$#
32

Prevalence Findings

Medications Findings
children (SAS 17%, IAS
12%, LAS, 15%)*

African American children
were less likely than
White children to have
diagnosis of ADHD
without learning
disability (LD) (OR
0.40).
No significant difference
in
ADHD with LD
between African
American and White
children (4% vs. 3%).
Overall African American
children were less likely
than White children to
be diagnosed with
ADHD (OR 0.82)
No significant difference
in
ADHD diagnosis
between White and

African American
children were less likely
than White children to

Source

Saloner et al.
(2013)

Siegel et al.
(2016)
[2011]$

Sample/ Setting

Measures

African American, 6.2%
Hispanic, 1.3% other
17 public elementary
schools from single
county in North Carolina

taking medication to
treat ADHD symptoms

Prevalence Findings
African American
children (OR 0.9)

Children age 3-17
Medicaid records with
N = 33,099 (1996); N =
ICD-9 diagnosis of
63,276 (2004)
ADHD on 2 distinct
1996: 48% White, 31%
dates within one year
African American, 21%
Prescription fill for at least
Hispanic; 2004: 40%
one ADHD medication
White, 24% African
American, 36% Hispanic
Florida ADHD related
Medicaid claims
Children age 3-17
Medical record with DSM- African American females
N = 133,091 annualized
IV-TR diagnosis of
were more likely than
estimate based on 32,047
ADHD
White females to be
records
diagnosed with ADHD
41.2% White, 24.1%
(aOR 1.2)***, as were
African American, 34.7%
males (aOR 1.17)***
Hispanic
Overall African American
2011 New York State
children were more
(NYS) Office of Mental
likely than White
Health biennial one-week
children to be diagnosed
Patient Characteristics
with ADHD (OR 1.14)
Survey- children
receiving care in the NYS
public mental health
system
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Medications Findings
be receiving medication
for ADHD (OR 0.7)***

White children were more
likely to receive
medication than African
American children in
both time periods ***

Source
Stein et al.
(2012)

Stevens et al.
(2004)
[1998]$#

Stevens et al.
(2005a)
[1999]$#

Stevens et al.
(2005b)

Sample/ Setting
Children age 6-12
N = 2,077
48% White, 32% African
American, 20% other
Claims from a Medicaid
managed behavioral
health organization in a
mid-Atlantic state for
children beginning
ADHD medication
treatment between
October 2006 and
December 2007
Children age 3-11
N = 26,441
76% White, 12% African
American, 12% White
Nationally representative
sample of primary care
visits from 1995-2000
Children age 3-18
N = 27,802
67.4% White, 16.5%
African American, 16.1%
Hispanic
1997-2000 MEPS data

Children age 3-18
N = 15,167
2000-2001 MEPS data

Measures

Prevalence Findings

Pharmacy data indicating
treatment with an
ADHD medication
Receipt of communitybased mental health
services for ADHD

Physician diagnosis of
ADHD using
International
Classification of
Diseases, 9th Revision
Prescription of a stimulant
medication
Outpatient visit for ADHD
Number of children
reported ever taking a
stimulant
Annualized number of
stimulant prescriptions
for children taking a
stimulant at least once
Parent report of shortacting vs. long-acting
stimulant medication
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Medications Findings
African American
children were more
likely to initiate
psychosocial treatment
alone than medication
treatment alone
compared to White
children (AOR 1.80)***

African American children
were less likely to
receive a diagnosis of
ADHD (OR 0.62);
however, this difference
was not statistically
significant
African American children
were less likely than
White children to be
diagnosed with ADHD
(2.1% vs. 5.1)* (OR
0.41)

African American
children were less likely
to be prescribed a
stimulant (OR 0.69);
however, this difference
was not statistically
significant
African American
children with ADHD
were less likely to
receive at least one
stimulant prescription
than White children with
ADHD (60.5 vs. 76.5)*
(OR 0.79)
There were no differences
between groups in
taking a short-acting vs.
long-acting stimulant

Source
Visser et al.
(2007)
[2003]$#

Walls et al.
(2018)
[2014]#

Wasserman, et
al. (1999)

Xu, et al.
(2018)

Sample/ Setting
Children age 4-17
Weighted national
prevalence based on data
from NSCH 2011

Children age 8-17
N = 2401
63.1% White, 14.3%
African American, 15.5%
Hispanic, 7.1% other
National representative
data from 2014 National
Survey of the Diagnosis
and Treatment of
Attention
Deficit/Hyperactivity
Disorder and Tourette
Syndrome
Children age 4-15
N = 22,059
401 pediatric practices
from 44 states, Puerto
Rico, and 4 Canadian
provinces

Children age 4-17
N = 186,457
49% White, 15.5% African

Measures

Prevalence Findings

Parent report of child with No significant difference
current ADHD diagnosis
in current or lifetime
Parent report of child ever
diagnosis of ADHD
having ADHD diagnosis
between African
Parent repot of child
American and White
taking
children (OR 0.98)
medication for ADHD
Parent report of child
taking medication for
ADHD

Physician report of child
with attention
deficit/hyperactivity
problems via post-visit
questionnaire

There was no difference in
physician report of
attention
deficit/hyperactivity
problems between White
and African American
children

Parent report of child with
physician diagnosis of
ADHD

In 2016, African American
children were more
likely than White
children to be diagnosed

[2016]$
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Medications Findings
African American
children with ADHD
were less than White
children likely to receive
a medication (OR 0.8)*

No significant difference
in current receipt of
medication for treatment
of ADHD between
African American and
White children (OR
0.65).
African American
children were less likely
to report ever taking a
medication for ADHD
(OR 0.3)*.

Source

Zablotsky, et
al. (2019)
[2013]$

Sample/ Setting
American, 27.5%
Hispanic, 8% other
Nationally representative
data from National
Health Interview Survey
1997-2016
Children age 3-17
N = 88,530
National Health Interview
Survey 2009-2017

Measures

Prevalence Findings

Medications Findings

with ADHD, however
the difference was not
significant (12.8% vs.
12%) (OR 1.07).

Parent report of ADHD

Zuvekas &
Vitiello. (2012)

African American children
were less likely than
White children to be
diagnosed with ADHD
(9.85% vs. 10.74%)*
(OR 0.92)

Children age 0-18, analysis Parent report of child
African American children
based on children age 5taking a stimulant with
were less likely than
17
pharmacy verification
White children to be
#
[2007]
N = 27,969
taking a stimulant (OR
42% White, 20% African
0.64)***
American, 33% Hispanic,
5% Other
1996-2008 MEPS Data,
analysis based on 2007
year
Zuvekas et al.
Children age 0-18, analysis Parent report of child
African American children
(2006)
based on children age 5taking a stimulant with
were less likely than
17
pharmacy verification
White children to be
[2000]#
N = 53,511
taking a stimulant (OR
1997-2002 MEPS Data
0.49)***
Note. Data years are presented in brackets. OR = Odds Ratio; AOR = Adjusted Odds Ratio; PR = Prevalence Ratio; $ = Summary
statistic included in diagnostic disparity trend analysis; # = Summary statistic included in medication treatment disparity trend analysis
*p<.05; **p<.01; ***p<.001
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Diagnostic Disparities
Twenty-one of the included studies reported ADHD prevalence by race. Current ADHD
diagnoses were reported from multiple data sources including parent report of child with a
diagnosis of ADHD (n=12), medical record documentation of an ADHD diagnosis (n=3),
diagnostic exam or interview for ADHD (n=3), Medicaid record with claim for ADHD (n=2), or
physician report of ADHD diagnosis (n=1). Within this sample of studies, ADHD prevalence
was significantly lower in African American children compared to white children in 14 (66.7%)
studies, while 5 studies (23.8%) reported no significant difference, and 2 studies (9.5%) reported
a significantly greater prevalence of ADHD among African American children than White
children. Incidence was reported in two studies, one which found a significant disparity for
African American children when measuring parent report of lifetime diagnosis of ADHD
(Danielson et al., 2018a), and one which found no difference (Visser et al., 2007).
ADHD prevalence disparities were also reported in the context of other variables. One
study (Froelich et al., 2007) reported prevalence by ADHD type, finding that African American
children were less likely than White children to be diagnosed with inattentive and hyperactive
types of ADHD, but no difference was noted in diagnosis of combined type ADHD. Two studies
explored the intersection of race, gender, and ADHD. Karnik et al. (2010) reported that African
American girls were less likely than White girls to be diagnosed with ADHD, though there was
no significant difference between races for boys. Conversely, Siegel et al. (2016) found that both
African American boys and girls were more likely than White children to be diagnosed with
ADHD. Pastor & Reuben (2005) explored the intersection of race with ADHD and learning
disabilities, finding that African American children were less likely than White children to have
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a diagnosis of ADHD without a learning disability, but there was no difference between races in
diagnosis of ADHD with a learning disability.
Aside from prevalence and incidence, diagnostic-type disparities were captured through
parent and teacher ratings of child symptoms. Three studies (Bax et al., 2019; Coker et al., 2016;
Cuffe et al., 2005) found African American parents were more likely to report children with
ADHD symptoms than White parents, however the difference was not statistically significant in
Cuffe et al.’s (2005) study. Bax et al. (2019) and Morgan et al. (2013) found no difference in
teacher ratings of ADHD behaviors between African American and White children.
Medication Treatment Disparities
Like ADHD diagnosis, medication treatment was measured in multiple ways. Receipt of
a medication was operationalized in different ways, inconsistently across studies. First, treatment
was defined as the presence or absence of medication treatment measured via parent report of
child taking an ADHD medication or taking a medication for symptoms of ADHD (n=19),
Medicaid claim for treatment with an ADHD medication (n=2), medical record showing
prescription of a medication for ADHD (n=1), or school record showing administration of a
medication for ADHD (n=1). In these cases, medication treatment included stimulant
monotherapy, alpha-2 agonists monotherapy, a combination of stimulant and alpha-2 agonist, or
any psychoactive medication, depending on the study. In this sample of 23 studies, fifteen (65%)
found that African American children with ADHD were significantly less likely than White
children with ADHD to be receiving a medication, while eight (35%) found no significant
difference between the groups. There were no studies finding that African American children
with ADHD were more likely than White children to receive medication treatment. Studies
exploring incidence of medication disparities reported fewer African American caregivers
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reported their children had ever received a medication for ADHD in their lifetime than White
caregivers of children with ADHD (Danielson et al., 2018b; Walls et al., 2018).
Treatment disparities were also quantified in terms of medication adherence and
discontinuation in three studies. Results of these studies consistently reported treatment quality
to be poorer among African American children compared to White children. Cummings et al.
(2017) found African American children were more likely than White children (OR 1.46) to
discontinue medication without reinitiation within a 300 day time period. Ji et al. (2018) also
found African American children were more likely to discontinue medication in a 300 day
period. Moreover, they concluded that African American children were less likely to receive
continuous medication treatment, and more likely to experience two or more gaps in treatment
during which a prescription was not filled for at least 14 days. Similarly, Palli et al. (2012) found
that gaps of 30 days in treatment were more common among African American children.
Four of the studies explored treatment disparities on more granular levels, such as
medication type. Davis et al. (2021) found that while there was no difference in treatment with
stimulants alone or in combination with alpha-2 agonists between groups, African American
children were less likely than White children to receive an alpha-2 agonist alone. Stevens et al.
(2005b) found that there was no difference in selection of a short-acting versus long-acting
stimulant between races. Lipkin et al. (2005) reported on dosing disparities by race and insurance
type, finding that African American children on Medicaid received significantly lower doses of
stimulants compared to other children, while those with private insurance received significantly
higher doses. Finally, Stein et al. (2012) looked at disparities in medication treatment versus
psychosocial treatment, concluding that African American children were more likely than White
children to initiate psychosocial treatment alone than medication treatment alone.
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Disparities over Time
The studies included in this review were published beginning in the late 1990s through
2021. However, when considering trends in disparities over time, the year of the data collection
was more valuable than publication date. Therefore, for this analysis, studies were included if
they reported the data year. For studies with data covering multiple years, the median year was
utilized. If there was an even number of years, the year greater than the median was used. This
analysis was also limited to studies that reported disparities in with a summary statistic (OR,
AOR, PR) or provided percentages that could be converted to an odds ratio.
There were 22 studies meeting the criteria to be analyzed for diagnostic prevalence
disparities over time. The data for these studies were collected over a 19 year period, between
1998 and 2017. Figure 2 shows the reported summary statistic of an ADHD diagnosis for
African American children compared to White children plotted against the data year. A
regression line has been fit to the data. The regression line represents the line of best fit, or the
line that can be drawn with the least amount of distance from the data points (Field, 2009). The
closer the data points are to the line, the stronger the relationship between the variables (Field,
2009). In Figure 2, the regression line has a positive slope over time, with the earliest data points
grouped around 0.5 and final data points grouped around 0.9. Overall, the data points cluster near
the trend line, indicating that there is likely some degree of association between time and a
reduction in reported ADHD prevalence disparities.
There were 19 studies meeting criteria to be analyzed for medication treatment disparities
over time. The data for these studies were collected over a 21 year period from 1996 through
2017. Figure 3 shows the reported odds ratios of medication treatment for ADHD for African
American children compared to White children plotted against the data year. The trend line has a
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positive slope over time, with the earliest data points grouped around 0.5 and final data points
grouped around 0.75. The data points in Figure 2 are spread further from the trend line,
indicating that there is likely no association between time and ADHD treatment disparities.

Figure 2
Diagnostic Disparity Summary Statistic by Year

Note. Each data points reflect the summary statistic (OR, AOR, or PR) from a discrete published
study.
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Figure 3
Medication Disparity Summary Statistic by Year

Note. Each data points reflect the summary statistic (OR, AOR, or PR) from a discrete published
study.

Discussion
Overall, this synthesis indicates that disparities exist in ADHD diagnosis and treatment
between African American and White children. Though studies including direct observation of
child behavior indicate African American children are equally if not more likely to present with
symptoms of ADHD (Bax et al., 2019; Coker et al., 2016; Cuffe et al., 2005; Morgan et al.,
2014), the majority of studies reviewed found they are less likely than White children to be
diagnosed with ADHD. Similarly, though African American children with ADHD are likely to
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benefit from medication treatment (Starr & Kemner, 2005), most studies found they are less
likely than White children to receive a medication. A number of socio-demographic
characteristics were analyzed in the studies reviewed in relation to both prevalence and
medication disparities. These characteristics include insurance status, continuity of insurance
coverage, household income, family composition, primary language spoken, region of the
country, urban or rural location, population density, physician density, parent highest education,
neighborhood safety, and neighborhood resources. Findings between studies conflicted on the
degree to which any one or combination of socio-economic factors explain ADHD prevalence or
treatment disparities.
The absence of consistent explanatory factors for disparities is consist with the IOM
(2003) definition of disparity as differences in healthcare quality that are not due to access
related factors. According to Coker et al. (2016), ADHD disparities exist independent of sociodemographics and mental health needs. For example, Assari & Caldwell (2019) concluded that
health gains associated with family income are smaller for African American families than
White. Thus, other factors must be considered. Provider bias has been suggested as a source of
ADHD disparities (Fadus et al., 2020), though observational studies suggest this may not be a
significant contributor (Garland et al., 2015; Sabin & Greenwald, 2012). Still, the inherent bias
of tools available to clinicians diagnosing children with ADHD may contribute to diagnostic
disparities and downstream treatment disparities. Diagnostic tools relying on parent report of
symptoms may be limited by culturally-based differences in parent ratings of ADHD symptoms
(Glasofer et al., 2021). In fact, culture likely exerts influence on ADHD disparities through
multiple channels. In a review of African American caregiver experiences of medication
treatment for children with ADHD, Glasofer et al. (2021) concluded that African American
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parental perspectives of ADHD and norms for child behavior differ from those of White parents,
and impact how they access care and make decisions about treating children with ADHD.
Moreover, experiences of ADHD as a form of social control among African American parents
impacts decision making and is likely reflected in prevalence and treatment disparities (Olaniyan
et al., 2007).
Disparities over Time
Based on this review, it appears there is a trend toward reduction in ADHD diagnostic
disparities over time. This is consistent with literature finding that ADHD prevalence has
increased in African American children at a greater rate than White children (Collins & Cleary,
2016; Xu et al., 2018). However, there does not appear to be a similar trend toward reduction in
ADHD medication treatment disparities. The increase in the use of stimulant medications over
time is more pronounced in White children than African Americans (Johansen et al., 2015;
Zuvekas & Vitiello, 2012). Moreover, this review indicates there are persistent disparities in
treatment quality for African American children with ADHD. Taken together, these findings
indicate that while there may be increased access to care and shifting perspectives of ADHD in
African American communities, significant gaps remain in ensuring equitable care for African
American children with ADHD.
Inconsistencies in Findings
Studies identifying greater ADHD diagnosis in African American children. While
the majority of studies indicated African American children were less likely to be diagnosed with
or treated for ADHD than White children, several notable inconsistencies were found among
studies. Nearly 25% of prevalence studies and 35% of treatment studies found equivalence
between groups. and two studies found that ADHD was diagnosed more commonly in African
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American children. Danielson (2018a) and Siegel et al. (2016) found that African American
children were more likely to than White children to be diagnosed with ADHD. Both of these
studies were published within the past five years, thus it is tempting to conclude that the trend
toward reduced disparities in recent history explains this outcome; however, Siegel et al. (2016)
used data from five years prior to publication, and most of the studies using data since 2011 did
not reach this conclusion. In fact, these two studies have little in common that can provide
insight into their unique findings. Of note, Siegel et al. (2016) was the only group who
specifically sampled from the medical records of a public mental health system. Thus, their
finding likely reflects that African American individuals are more likely to access psychiatric
care in a public health system as opposed to private practice psychiatric or primary care
practitioners compared to White children, who are also more likely to be covered by private
insurance (Siegel et al., 2016). Conversely, Danielson et al. (2018a), was one of seven studies
utilizing three nationally representative databases to measure parent report of a child with an
ADHD diagnosis in a community based sample, but was the only one of these to report African
American children were more likely than White children to have a diagnosis of ADHD. Of the
remaining six similar studies, five found African American children to be less likely than White
children to have a diagnosis of ADHD. Xu et al. (2018) reported no difference by race.
Danielson et al. (2018a) suggest their finding could have resulted from a methodological change
from previous versions of the National Surveys of Children’s Health (internet and mail collected
survey responses vs. phone). Of note, Danielson et al.’s (2018a) sample was the only one of this
group to overrepresent White children and underrepresent African American children, thus the
racial composition may have impacted study findings. Additionally, given that Danielson et al.
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(2018a) and Xu et al. (2018) utilized data from 2016, the findings may reflect a trend toward the
recent reduction in diagnostic disparities.
Studies identifying equivalence in ADHD diagnosis between groups. Five studies
reported no difference in ADHD diagnoses between African American and White children.
Remarkably, four of the five used data from 1999 or earlier, thus these studies are not temporally
related to the trend toward reduction in disparities over time. Otherwise these studies are
heterogenous in methodology. The samples were drawn from a single juvenile justice setting,
elementary schools in a single county, two nationally representative samplings of primary care
records, and one nationally representative community based survey. ADHD diagnosis was
measured through direct interview of the child, parent report of physician diagnosis, medical
record with physician diagnosis, and physician survey. The methodologies may have resulted in
samples that limit generalizability of study findings. For example, Karnik et al.’s (2010) sample
was composed of only 17% White children while African American children represented 28% of
the sample. White children were overrepresented in Rowland et al. (2002), Stevens et al. (2004),
and Wasserman et al.’s (1999) samples compared to national data (Anne E. Casey Foundation,
2019). Only Xu et al. (2018) included a representative sample. Moreover, samples ranged in size
from 790 children (Karnik et al., 2010) to nearly 200,000 (Xu et al., 2018). Aside from Xu et
al.’s study (2018), it seems an absence of significant findings amid a majority of studies that
identified significant disparities in ADHD diagnosis between African American and White
children may result from the heterogeneity and limitations of methodologies.
Inconsistencies in treatment disparity findings. Again, the majority of studies
exploring disparities in medication treatment found African American children were less likely
than White children to receive a medication. There were eight studies that did not detect a
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significant difference in receipt of a medication for ADHD between African American and
White children. Of these, six studies reported summary statistics, and all found African
American children were less likely to receive a medication though the difference was not
statistically significant. The data trend toward reduction in medication disparities over time was
not as notable as the prevalence trend. In parallel with this, there was no trend in findings of
equivalence over time, with study data years spread from 1998 through 2016. The data sources,
outcomes measured, and sample sizes between those studies reporting a significant disparity or
equivalence varied similarly. White children were overrepresented in half of the studies reporting
equivalence compared to 1/3rd of studies reporting disparities in medication treatment. African
American children were overrepresented in 42% of studies reporting significant disparities but
none of the studies reporting equivalence. These differences in sampling indicate that sample
racial composition may influence study findings. Also, of note, six of the eight studies reporting
equivalent findings included children younger than age six, while only four of the 12 studies
reporting significant disparities included children this young. This is significant as the American
Academy of Pediatrics (Wolraich et al., 2019) recommends behavioral interventions prior to
medication treatment in children younger than six. Thus, it may be that inclusion of preschool
age children (5 years old and under) along with school age (6-11 years old) and adolescent
subjects (12-18 years old) skews data on ADHD medication disparities. Of the studies that
included individuals age 18 and over, three consistently found African American children were
less likely to be diagnosed with ADHD than White children, and three of four found African
American children were less likely receive treatment than White children. Thus, it does not seem
the inclusion of individuals who would not typically be considered children, and who would be
able to make decisions independently skewed study findings.
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Limitations of the studies
Generalization of the findings from this literature may be impacted by several limitations.
Methodologies were heterogenous in key aspects of sampling, data collection, and measurement.
In regard to sampling, fewer than half of the studies included representative samples. While
oversampling of minorities may be necessary to recruit sample sizes sufficient for analysis (Chen
et al., 2020), studies in which African American children were underrepresented or White
children were overrepresented may cause an over or underestimation in the degree of disparities.
Additionally, there is evidence that disparities differ by geographic region (Danielson et al.,
2018a), thus local, regional, and state-based samples may not provide an accurate depiction of
disparities across the US.
Data collection methods may also contribute to limitations in findings. Data collected
from medical interfaces, such as Medicaid claims and medical records may miss individuals who
were not accessing healthcare. Access issues confound findings related to disparities. Individuals
who are uninsured or underinsured are less likely to receive care (Healthy People 2030, ND).
Therefore, relying on insurance claims or medical records disproportionately excludes
individuals most vulnerable to health inequities. Community-based samples may provide a more
generalizable reflection of the population; however, surveys utilizing parent responses are
relying on individuals for accuracy of information, and a willingness to participate in research
which is reduced in African Americans (Branson et al., 2007).
There was a lack of standard tools or instruments for measures of prevalence or
treatment. Issues with the measurement of ADHD in African American populations limits the
validity of prevalence findings. Studies have found that African American parents’ ratings of
child behavior differ significantly from White parents in ways that yield different results on
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ADHD screening instruments, such that children with similar underlying needs may be treated
differently (Harvey et al., 2013; Hillemeier et al., 2007; Wiesner et al., 2015). This issue will
persist until there is a more culturally competent approach to diagnosis of ADHD in African
Americans (Miller et al., 2009). Studies of medication treatment presented unique limitations.
Inconsistencies in the operationalization of medication treatment limit the validity of treatment
related findings and the ability to compare results between studies. Most studies captured the
prescription of a medication or fill of a prescription, either as documented in the medical record
or insurance claim. These data sources do not reflect if a child is taking the medication. Where
parents were surveyed on medication receipt, the question was framed as a binary response, and
did not capture disparities in treatment type, dosing, persistence, or discontinuity. Thus, it is still
not possible to determine if African American children with ADHD are receiving equitable care.
The few studies that did explore measure of treatment quality also utilized inconsistent measures
for outcomes such as treatment discontinuation and medication gaps. In addition, no data was
collected regarding reasons for treatment decisions, rendering it difficult to assess the science.
However, the studies of treatment quality indicate there are significant disparities in medication
dosing practices and medication taking outcomes (Cummings et al., 2017; Ji et al., 2018; Palli et
al., 2012). This small set of studies is important in identifying the future direction for ADHD
disparity research.
Limitations of the review
This review is also not without limitations. First, only peer reviewed studies were
included which limits the chances that null and negative findings were represented in this review.
However, a number of included studies did report null and negative findings. Additionally, this
review assumed a position that disparities reflect underdiagnosis or treatment in African

49

Americans rather than exploring the possibility that they reflect overdiagnosis or treatment in
White children. Finally, this review was limited to disparities between African American and
White children. The findings of this review cannot be generalized to other minorities. Disparities
in other groups may result from different factors such as primary language, different cultural
beliefs and expectations related to behavioral health, and different experiences of discrimination
and racism. Moreover, through the exclusion of qualitative studies, it does not explore reasons
for disparities or heterogeneity of experiences within African Americans. Despite these
limitations, this review provides a rigorous and robust synthesis of the existing research on
diagnostic and medication treatment disparities between African American and White children in
the US.
Recommendations for Practice and Future Research
The findings of this review suggest that policy and practice changes are working to
reduce disparities in ADHD diagnosis. Programs such as Healthy People 2020 have prioritized
the health of children and adolescents, have established objectives, and provided resources in
order to achieve equitable health in this population (HealthyPeople.gov, 2021). For example,
Healthy People 2020 includes an objective to increase the percent of adolescents who’ve had a
wellness checkup in the past year from 68.7% to 75.6% (HealthyPeople.gov, 2021). This
objective has already been exceeded among African American children. As most pediatric
ADHD diagnoses are made and treated by primary care physicians (Patel et al., 2017), programs
like Healthy People 2020 indirectly impact ADHD disparities.
However, persistent disparities are complex and will not be eliminated solely by
equalizing socio-economic status and access. Based on the National Institute of Minority Health
and Health Disparities (NIMHD) research framework, existing inequities result from the
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influence of biological, behavioral, physical environment, sociocultural environment, and the
health care system including family, community, and social norms (NIMDH, 2017). The work of
clinicians and policy makers moving forward must be to reduce the impact of bias, mistrust, and
historical trauma on ADHD disparities without assuming a paternalistic approach. Rather,
attention must be given to eliminating structural racism, bias, and discrimination, and supporting
African American families to leverage socio-economic status to improve health (Assari &
Caldwell, 2019).
Continued research on diagnostic and medication treatment disparities in ADHD should
further evaluate trends moving forward, should address the limitations identified in this review,
and should be informed by a synthesis of the literature on disparities in other minority groups.
Research on medication treatment disparities will require greater attention. A much deeper
assessment of prescription practices and medication-taking behaviors is required to determine the
status of health equity for children with ADHD, and what steps will need to be taken to address
persistent disparities. Interventions to reduce the impact of clinician bias will need to be tested,
as well as studies to explore how experiences of racism impact medication decision making, and
how to restore relationships between the African American and medical communities.
Interventions are required to increase minority representation among ADHD clinicians and
researchers. Finally, there is a need to conceptualize race beyond a set of unchangeable
biological characteristics (Sen & Waslow, 2016). Sen and Waslow (2016) assert that future
research should better connect race and causation by exploring within-group variation. Lipkin et
al. (2005) illustrated this by identifying an interaction between race and insurance type. Future
research should explore within group variations to identify factors contributing to medication
decision making among African Americans.
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Conclusion
This review found that there are diagnostic and medication treatment disparities between
African American and White children with ADHD. Interestingly, it seems that diagnostic
disparities are improving over time. Despite the increase in diagnosis of ADHD among African
American children, treatment disparities persist. This review demonstrates that further research is
required to fully describe and intervene on ADHD treatment disparities. Though progress has
been made since research on ADHD disparities began more than 20 years ago, this review
indicates there is work to be done to ensure equitable healthcare for children with behavior
health needs.
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Chapter 3: Manuscript 2
Medication Decision Making among African American Caregivers of Children with ADHD: A
Review of the Literature
Building on findings from Manuscript 1, the second manuscript synthesizes fourteen
studies on African American caregiver experiences of MDM for their children with ADHD. This
review resulted in three main themes including (a) fundamental perspectives of ADHD, and
cultural norms for child behavior; (b) the impact of fundamental perspectives on MDM in
ADHD; and (c) ADHD diagnosis and treatment as forms of social control. The manuscript
provides recommendations for practice including provision of patient centered care, exploration
of ADHD knowledge and explanatory models, and efforts to increase diversity in mental health
professionals. Future research should include development of culturally sensitive ADHD rating
scales, exploration of ADHD MDM as a process rather than an outcome, and identification of
withing group variations in factors associated with MDM.
In October, 2021 this manuscript was published in the Journal of Attention Disorders, a
peer-reviewed journal focused on basic and applied research related to attention disorders (Sage,
2021). Copyright permission was obtained from the publisher to include this manuscript in this
dissertation (Appendix C). Written permission was obtained from the coauthors to include this
manuscript in the dissertation (Appendix B & Appendix D).

Glasofer, A., Dingley, C., & Reyes, A. T. (2021). Medication decision making among African
American caregivers of children with ADHD. Journal of Attention Disorders, 25(12),
1687-1698. DOI: 10.1177/1087054720930783
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Abstract
Background: Significant pharmacotherapy disparities exist among children from ethnic
minorities with ADHD. Objective: The purpose of this review is to synthesize existing evidence
on African American caregiver medication decision making (MDM) for children with
ADHD. Method: Databases queried for this review included the Cumulative Index of Nursing
and Allied Health Literature (CINAHL), PsychINFO, PubMed, and Education Resources
Information Center (ERIC). Information regarding the unique culturally specific barriers and
supports to MDM were examined through the relevant literature search. Results: Fourteen
articles were included in this review (7 observational studies, 4 qualitative studies, 3 mixed
methods studies). Three main themes were identified which include (a) fundamental perspectives
of ADHD, and cultural norms for child behavior; (b) the impact of fundamental perspectives on
MDM in ADHD; and (c) ADHD diagnosis and treatment as forms of social control.
Conclusions: Evidence-based recommendations for clinicians are provided, along with direction
for future research.
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Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common pediatric
neurobehavioral disorder in the United States, resulting in significant morbidity for children and
families (Wolraich et al., 2019). An estimated 6.1 million U.S. children have a current or prior
diagnosis of ADHD (Danielson et al., 2018a). Prevalence data indicate that ADHD is diagnosed
less frequently in African American children than White children, with odds of an ADHD
diagnosis for African American compared to White children ranging from 0.30 to 0.62 (Collins
& Cleary, 2016; Morgan et al., 2014).
While African American children are less likely to receive a diagnosis of ADHD than
White children, this does not indicate they are less likely to express symptoms of the disorder.
Observational studies of childhood behavior indicate that symptoms of ADHD are expressed
equally across ethnicities (Bax et al., 2019; Morgan et al., 2014). One meta-analysis concluded
that African American youth had more symptoms than White children (Miller et al., 2009). It
does not appear that confounding variables, such as birth weight, income, insurance coverage, or
learning disability account for diagnostic differences (Miller et al., 2009). One potential
explanation is the validity of standardized ADHD rating scales in African American children.
Factor structure and individual item performance of standardized instruments may not measure
ADHD severity equally across races (Hillemeier et al., 2007; Miller et al., 2009, Wiesner et al.,
2015). For example, differences in cultural processes behind parental and teacher ratings of
behaviors may yield differing thresholds for acceptability of “argued or talked back” on a scale
(Wiesner et al., 2015).
In addition, specific factors such as differences in parental perceptions of ADHD
symptoms between African American parents and White parents and teachers have shown to be
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associated with lower rates of ADHD diagnoses among African American children (Bax et al.,
2019; Morgan et al., 2013; Hillemeier et al., 2007; Kang & Harvey, 2020). For example,
perceptions of hyperactivity in African American children are not necessarily perceived as
problematic by African American parents but rather encouraged as part of the child’s
expressiveness (Boykin & Bailey, 2000; Kang & Harvey, 2020). African American parents rate
their knowledge of ADHD lower compared to their White counterparts (Bailey & Owens, 2005;
Turner et al., 2015). Additionally, lower levels of trust in medical providers, and difficulty
accessing medical care and information among African American caregivers serve to further
disparities in receipt of an ADHD diagnosis (Bax et al., 2019). This literature review will provide
an in-depth exploration of potential explanations for differing perceptions of African American
caregivers on ADHD related behaviors.
Access to care is another factor that may result in diagnostic disparities. Siegel et al.
(2016) found that children from ethnic minorities were actually more likely to be diagnosed with
ADHD. Their sample was drawn from a publicly funded mental health service (Siegal et al.,
2016), as opposed to results from other studies that draw from primary care clinics in which
White children are more likely to be diagnosed with ADHD (Bax et al., 2019; Coker et al.,
2016). Moreover, children living below the poverty level, who lack health insurance, who live
with a stepparent, and who live in unsafe neighborhoods are less likely to have a parent report of
ADHD, regardless of ethnicity (Collins & Cleary, 2016). Thus, reporting disparities may be a
reflection of socioeconomic status and access to care rather than a primary function of ethnicity.
Pharmacotherapy is one element of a comprehensive treatment plan for ADHD (Wolraich
et al., 2019). Pharmacological treatment of ADHD is associated with positive health, safety,
academic, occupational, social, and family outcomes (Fridman et al., 2017a; Prasad et al., 2013;
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Quinn et al., 2017; Ruiz-Goikoetxea et al., 2018; Shaw et al., 2012; Silva et al., 2015). There are
multiple components of pharmacotherapy that require caregiver decision-making related to
medication initiation, persistence, adherence, and discontinuation. For the purposes of this
discussion, these terms are defined as follows: medication initiation- the first fill of a prescription
and provision of the first dose, medication persistence- the period of time between medication
initiation and discontinuation, medication adherence- the extent to which actual dosing
corresponds to prescribed dosing, and medication discontinuation- the final dosing of a
medication (Raebel et al., 2013; Schmittdiel, et al., 2013; Vrijens et al., 2012). Regarding
medication initiation, an estimated 62% of children with a current diagnosis of ADHD are taking
medication for their ADHD (Danielson et al., 2018a). In terms of treatment persistence and
adherence, treatment duration for ADHD averages 136 days, and non-adherence estimates range
between 15 and 83% (Atzori et al., 2009; Spencer et al., 2011; Usala, et al., 2009). These
numbers likely do not reflect sufficient treatment (Wolraich, 2019). Moreover, children with
ADHD from ethnic minorities are significantly less likely to receive pharmacotherapy than their
White counterparts (Coker et al., 2016). The odds of taking a medication for ADHD in African
American children compared to White children range from 0.35-0.65 (Morgan et al., Staff, et al.,
2013; Walls et al., 2018). In addition, African American children are more likely to demonstrate
low adherence and early discontinuation of ADHD medication regimens than their White and
Hispanic counterparts (Cummings et al., 2017; Ji et al., 2018; Saloner et al., 2013).
While literature on medication taking experiences in ADHD exists, it has not specifically
examined the unique perspective of African American caregivers (Gajria et al., 2014; Rashid et
al., 2018b). A recent integrative review examined 32 studies focused on family processes
including identification, care-seeking, treatment preferences, and engagement with services

57

among ethnically diverse youth with ADHD (Paidipati et al., 2017). While their review is
comprehensive, it generalizes across ethnic minorities and does not specifically explore
medication decision making (Paidipati et al., 2017). Given the evidence supporting the existence
of pharmacotherapy disparities between African American and White children with ADHD, a
specific review of the literature exploring perspectives of African American caregivers of
children with ADHD is needed to better describe what is currently known, and to identify gaps in
knowledge. In order to address ADHD pharmacotherapy disparities, the unique experiences and
perspectives of ethnic minorities must be understood.
While disparities exist across multiple ethnicities, there are cultural and historical factors
for ADHD medication disparities exclusive to African American individuals. In explaining these
factors, Suite et al. (2007) reference an 1840 U.S. census report that falsely claimed insanity
rates among African Americans increased the further north they lived. Suite et al. (2007)
describe the medicalization of typical behavior among African Americans that did not suit White
Americans, such as developing a diagnosis for the desire to escape slavery. Thus, the fear of
using medical diagnoses to achieve control of African American’s has historical precedence. A
lack of trust in healthcare professionals, in the diagnoses they render, and in the treatments, they
recommend contributes to pharmacotherapy disparities for ADHD (Suite et al., 2007).
Inadequate knowledge and understanding of these barriers hinder mental health treatment of
African American children with ADHD (Rostain et al., 2015). Moreover, caregivers are
predominantly the ones to make medication decisions for children with ADHD (Berger et al.,
2008). Therefore, the purpose of this review is to synthesize existing evidence on African
American caregiver medication decision making (MDM) for their children with ADHD.
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Methods
The following inclusion criteria were applied to the literature search: (a) articles written
in English; (b) peer-reviewed or clinical practice guidelines from professional associations; (c)
research or theoretical reports on African American caregiver experiences with children with
ADHD; and (d) focused on ADHD medication. Databases queried included the Cumulative
Index of Nursing and Allied Health Literature (CINAHL), PsychINFO, PubMed, and Education
Resources Information Center (ERIC). Keywords used in the search included the terms
attention-deficit/hyperactivity disorder, ADD, and ADHD along with each of the following
terms: diagnosis, prevalence, medication, stimulant, treatment, outcome, adherence, minority,
disparity, African American, and caregiver. No year limits were placed on articles, however
literature that was published up through 2019 were included. Titles and abstracts were screened
for relevance prior to full review for inclusion. Manual searches from the reference lists of
articles that met the above criteria were also conducted for relevant works. In total, 14 out of 915
articles met the inclusion criteria for full text review and were synthesized in this paper. After
removing duplicates, 824 records were excluded because they lacked a primary focus on ADHD
medication in children from the perspective of African American caregivers.
The 14 articles underwent an extensive comprehensive data extraction and evaluation
process. Data extracted from each study included: study aim, design and methods, sample and
setting, and main findings and outcomes. The categories of data were analyzed through iterative
comparisons across primary sources. The main findings and outcomes were compared across
studies and similar data grouped together as categories that were compared and further
synthesized. The authors conducted group discussions to draw inferences from the data, using a
narrative approach. Discussion of the preliminary categories and thematic analysis continued,
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until consensus was reached, and the findings of the review were confirmed. The final 14 articles included 7 non-experimental
quantitative studies, 4 qualitative studies, and 3 studies utilizing mixed methods (Table 2).

Table 2
Table of Evidence
Authors

Main Aim

Berger-Jenkins
et al. (2012)

Explore minority
parents’
knowledge and
perceptions of
ADHD

Bussing et al.
(2003a)

Describe whether
parents’
understanding or
explanatory
models contribute
to gender and
cultural variations
in help-seeking
for children with
ADHD.

Study Design and
Methods
Quantitative- prospective
cohort

Mixed methods
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Sample and Setting

Main Findings and Outcomes

Parents of children with
ADHD diagnosis not
using medication or
psychological treatment
N = 70
57.1% Hispanic, 34.3%
African American
Primary care and mental
health specialty clinics at
New York City hospital
Parents of elementary
school students at high
risk for ADHD
N = 182
41% African American,
59% White
Single elementary school
district in Florida

Parents were hesitant to start a
medication based on what
they heard about Ritalin
Parents who were hesitant to
start
Ritalin were 2.4 times less
likely to attend follow-up
appointments

African American parents
were less
likely to use medical labels
for child’s condition (OR
0.26)***
African American parents
were
more likely to say they did
not know the cause of
child’s condition (OR
2.7)**

Authors

Bussing et al.
(2007)

Main Aim

Explore cultural
variance in
parental health
beliefs,
knowledge, and
information
sources related to
ADHD.

Study Design and
Methods

Sample and Setting

Quantitative- cross
sectional

Parents of children with and
without ADHD
N = 1,615
41% African American,
59% White
Single elementary school
district in Florida
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Main Findings and Outcomes
African American parents
were less
likely to request medication
(OR .26)*** treatment or
school intervention (OR
.39)**.
African American parents
were less
likely to endorse that
ADHD can be treated by
medications (OR .7)*
African American parents
were less
likely to denounce sugar as
cause for ADHD symptoms
(OR .3)***
African American parents
were less
likely to report knowing a
lot about ADHD (OR
.4)***, ever hearing about
ADHD (OR .1)***, or
recently hearing about
ADHD (OR .5)***
African American parents
were less
likely to report a diagnosis
of ADHD for themselves
(OR .2)***, family
members (OR .7)*, or others
(OR .4)***

Authors

Bussing et al.
(1998)

Main Aim

Describe variations
in ADHD
knowledge,
information
sources, and
explanatory
model by
ethnicity and
socioeconomic
status

Study Design and
Methods

Sample and Setting

Mixed Methods

African American and
White caregivers of 2nd4th grade children with
learning disabilities
Phase 1 n = 499, Phase 2 n
= 139
46% African American,
54% White
Single school district
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Main Findings and Outcomes
Fewer concerned African
American
parents received information
on ADHD from written
materials*, hospitals or
clinics**, public health
departments***, friends*,
teachers and schools**, and
the internet**.
African American caregivers
were
less likely to have exposure
to individuals with ADHD
or information about
ADHD***, and rated
ADHD knowledge lower
than White parents***
African American caregivers
were
more likely to attribute
sugar as a cause of
ADHD***, less likely to
indicate a genetic cause* or
use a medical label for
ADHD (OR 0.24)***, and
more likely to label the child
as “bad”***
African American caregivers
were

Authors

Main Aim

Study Design and
Methods

Bussing et al.
(2003b)

Describe helpMixed Methods
seeking and
explore variations
in help-seeking
for ADHD by
sociodemographic
variables, and
describe barriers
from parents who
have not engaged
in treatment

Bussing et al.
(2012)

Explore how
ADHD
knowledge,

Sample and Setting

Main Findings and Outcomes
less likely to endorse
medication as a treatment
for ADHD***
Fewer African American
parents
received information from
physicians**, library***,
medical journals ***, and
newspapers***. More
African Americans received
information from public
health departments**
African American children
were
less likely to have ADHD
symptoms recognized*,
evaluated***,
diagnosed***, or
treated***.
Having a negative
expectation* was
the only significantly
different barrier between
African American and
White parents of children
with ADHD not receiving
services.

Phase 1: African American
or White K-5th grade
children at high risk or
diagnosed with ADHD,
Phase 2: African
American or White
children with ADHD not
receiving services.
Phase 1: N = 389, Phase 2:
N = 91
Phase 1: 52% African
American, 48% White;
Phase 2: 50% African
American, 50% White
Single school district in
Florida.
Adolescents classified as
White parents were more
high (56%) and low
likely
(44%) risk for ADHD and

Quantitative- cross-
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Authors

Main Aim
perceptions, and
cues to action
vary by
sociodemographic
characteristics

Study Design and
Methods
sectional design using
data from longitudinal
study

dosReis et al.
(2006)

Explore caregiver
attitudes,
satisfaction,
knowledge, and
medication
experiences of
stimulant
medications for
ADHD

Quantitative- crosssectional

dosReis et al.
(2007)

Develop a theory of
coming to terms
with ADHD
diagnosis among

Qualitative- Grounded
theory

Sample and Setting

Main Findings and Outcomes

their parents selected
from longitudinal cohort
study of access to care for
ADHD.
N = 347
36% African American,
64% White
Single school district in
Florida
African American
caregivers of children
with ADHD who had
received a medication for
ADHD within the past 12
months.
N = 48
Urban academic primary
care clinic in Baltimore,
Maryland

to have heard of ADHD OR
6.4)***, know some or a lot
about ADHD (OR 2.8)***,
and know someone with
ADHD (OR 5.7)**
White parents were less likely
to
endorse sugar as a cause for
ADHD (OR .5)**
Caregivers believed stimulants
would improve ADHD
symptoms (88%), were safe
if recommended by a
physician (90%), and would
recommend stimulant
medication for a child with
ADHD (63%).
Majority were hesitant to
initiate
medication (71%), and
would prefer counseling
over medication (54%).
Negative perceptions included
concern for drug abuse
(17%), side effects (21%),
and overprescribing of
medications (22%).
Parents who viewed behaviors
as
ADHD symptoms with a
medical or biological cause

African American
caregivers of children
newly diagnosed with
ADHD
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Authors

Main Aim

Study Design and
Methods

Sample and Setting

urban African
American
caregivers of
children with
ADHD.

Graves. (2017)

N = 26
Clinics associated with an
urban academic medical
center in Baltimore,
Maryland.

Develop a theory of Qualitative- Grounded
help-seeking
theory
processes among
African American
single mothers
living in poverty
seeking mental
health services for
their children.

African American
impoverished single
mothers seeking mental
health services for their
children with ADHD or
anxiety and comorbid
personality disorder,
autism, or Tourette
syndrome
N = 11 mothers, 12 children
(ADHD = 11, anxiety =
1)
Public housing authority in
urban area.
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Main Findings and Outcomes
engaged in medical
interventions.
Parents who attributed
behaviors as
atypical but not symptoms
of ADHD focused on
religious beliefs or
discipline to manage
behaviors.
Some parents sought medical
treatment as a result of 3rd
party intervention but did
not perceive behaviors as
problematic.
Medication decision-making
was
influenced by perceptions,
beliefs, and personal
experiences with
medication; the mother’s
relationship with the mental
health provider; competence
in managing the child’s
behavior;
and informal support
system.
Participants expressed
reservations
about medications and a
belief in discipline over
medication.

Authors

Hillemeier et
al. (2007)

Main Aim

Item Response
Theory was used
to determine
whether
differential item
function (DIF)
existed between
African American

Study Design and
Methods

Sample and Setting

Quantitative- crosssectional design using
data from longitudinal
study
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Parents of children enrolled
in longitudinal study of
children at risk for
emotional/behavioral
problems
N = 1070
51% African American,
49% White

Main Findings and Outcomes
Medication was chosen from a
need to manage behaviors,
observations of progress of
others on medication and
other personal experiences,
or pressure from a third
party.
Influences on remaining on
treatment included finding
the right medication,
relationship with the mental
health
provider/school/pediatrician,
and informal supports.
Mothers were concerned with
side
effects and lack of followup with providers.
Continued treatment was
influenced by perceived
improvement in symptoms
and future orientation or
third party pressure.
At the same level of
hyperactivity,
White parents were more
likely to endorse
hyperactivity items than
African American.
Except for concentration, each

Authors

Main Aim

Study Design and
Methods

and white
respondents on
the DISC
assessment of
ADHD
symptoms.

Krain, Kendall,
& Power.
(2005).

Explore treatment
acceptability and
parent report of
treatment pursuit
at 3-4 months
after diagnosis
and treatment
recommendation.

Quantitative- prospective
cohort
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Sample and Setting

Main Findings and Outcomes

Elementary schools in 4
states in the US.

subscale contained one item
that demonstrated DIF, such
as excessive talking at
home.
Removing items exhibiting
DIF in
the hyperactivity scale
reduced racial difference in
means and differences were
no longer significant.
Medication disparities were
reduced when items
exhibiting DIF were deleted.
White parents rated treatment
acceptability of medication
significantly higher than
non-White, primarily
African American,
parents.**
White children were
significantly
more likely to pursue
medication therapy than
non-White children.**
Parental rating of acceptability
of
medication accurately
predicted pursuit of
medication at 3-4 months in
83.7% of cases.

Caregivers of children
newly diagnosed with
ADHD and no prior
treatment
N = 55
75% White, 20% African
American, 5% other
ADHD center at a large
metropolitan pediatric
hospital.

Authors

Main Aim

Study Design and
Methods
Quantitative- crosssectional

Sample and Setting

Main Findings and Outcomes

Nationally representative
sample of communitybased adults
N = 1,139
Participants in the National
Stigma Study- Children

African American were less
likely
to be aware of ADHD (OR
.50)*
African Americans were less
likely
than white respondents to
say that ADHD is real (OR
.58)*.
Treatment preferences were
strongly associated with
belief about whether ADHD
is real or not.
Parents who viewed ADHD as
a
medical illness endorsed a
biological explanation of
behavior, and utilized
medication
Parents who viewed behaviors
as a
normal stage of
development expected the
behaviors to be cured or
outgrown without treatment
Most parents attributed
behavioral
problems to poor parenting,
such as a lack of attention or
appropriate discipline.

McLeod et al.
(2007)

Explore general
public
knowledge,
beliefs, and
treatment
preferences for
ADHD, and
identify variations
by
sociodemographic
characteristics.

Mychailyszyn
et al. (2008)

Develop a theory
about how
African American
mothers
conceptualize
their child’s
ADHD and how
this relates to
treatment

Qualitative- grounded
theory

African American
caregivers of children
with ADHD
N = 34
Outpatient offices in an
inner-city community.

Olaniyan et al.
(2007)

Describe how
African American
parents view
behavior
problems and

Qualitative

African American parents
N = 31
Primary care pediatric
clinics in the BaltimoreWashington Metropolitan
area.
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Authors

Main Aim

Study Design and
Methods

Sample and Setting

their management
in children.

Main Findings and Outcomes
Views of an ADHD diagnosis
were
mixed, with some feeling
that ADHD was not
sufficiently diagnosed and
others that it is not a real
diagnosis.
Racial concerns existed about
the
stigma of ADHD, and that
medicalization of behaviors
is a form of social control
with historical routes.
Participants expressed distrust
of
physicians and
pharmaceutical companies.
Negative opinions of
medication
were prevalent, with
concerns for sedation and
addiction.
Medication was viewed as a
last
resort and a short-term
solution.
Medication was seen as a way
to
control classroom behavior
for ineffective teachers and

69

Authors

Pham et al.
(2010)

Main Aim

Explore cultural
differences in
parental beliefs of
causes and
treatment of
ADHD, and the
relationship
between beliefs
and treatment
preferences

Study Design and
Methods

Sample and Setting

Quantitative- crosssectional

Parents of children with and
without ADHD
N = 119
54% White, 28% African
American, 18 % other.
Mid-Michigan community.

Main Findings and Outcomes
school systems, and to make
the teacher’s job easier.
No significant differences
between
ethnic groups regarding
beliefs of causes of ADHD
or medication treatment.
Significant relationship
between
belief in a biological/genetic
cause for ADHD and
preference for a medication
only treatment plan*.

Note. OR = Odds Ratio
*p<.05; **p<.01; ***p<.001

Results
Based on the results of our literature search and review, we observed that African American caregiver decision making
regarding pharmacotherapy for children with ADHD is largely based on caregivers’ inadequate scientific knowledge of ADHD,
personal stigmatized beliefs about medication treatment, and public stigma of ADHD diagnosis and treatment. To this end, the focus
and findings of the literature in this review was synthesized into three overarching themes that describe the evidence related to
medication decision making in African American caregivers: (a) fundamental perspectives of ADHD, and cultural norms for child
behavior; (b) the impact of fundamental perspectives on MDM in ADHD; and (c) ADHD diagnosis and treatment as forms of social
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control. These three overarching themes demonstrate factors that contribute to medication
decision making and potential pharmacotherapy disparities. Additionally, these three themes
concur with findings about key factors affecting increased help-seeking behaviors of ethnic
minority children and caregivers with ADHD treatment and mental health services (Eiraldi et al.,
2006).
More particularly, the quantitative studies in our literature review used cross-sectional
methods to assess beliefs about ADHD and medications in minority caregivers, and contrast
them to their White counterparts (Bussing et al., 1998; Pham et al., 2010). Qualitative studies
focused on specific experiences of African American families and communities related to ADHD
(dosReis et al., 2007; Olaniyan et al., 2007).
Fundamental Perspectives of ADHD and Cultural Norms for Child Behavior
Fundamental perspectives of ADHD and cultural norms for child behavior was the first
overarching theme that emerged from our analysis of the literature synthesis and accounts for the
caregivers’ perceptions about ADHD. This theme is comprised of three sub-themes: (1) ADHD
knowledge: pertains to the caregivers’ level of scientific knowledge of ADHD and exposure to
medical information about ADHD; (2) explanatory models of ADHD: pertains to the caregivers’
health beliefs about ADHD and seeking medical care related to ADHD; and (3) cultural
differences in perceptions of ADHD: pertains to the differences in perspectives about ADHD
between African American caregivers and other racial groups.
ADHD knowledge. The majority of empirical evidence of parental knowledge of ADHD
among African Americans is based on the works of Bussing and colleagues (Bussing et al., 1998,
2003a, 2003b, 2007, 2012). McLeod and colleagues (2007) were the only other team to assess
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racial differences in ADHD knowledge. However, their study was limited to investigating
whether participants had ADHD knowledge or not. (McLeod et al., 2007).
In many quantitative studies, knowledge level of ADHD among different racial groups
was measured by parent or investigator ratings, reports of exposure to ADHD information and
information source, or exposure to others with ADHD (Table 2, Bussing et al., 1998, 2003a,
2007, 2012; McLeod et al., 2007). Findings from these studies demonstrated that African
American parents had lower ADHD knowledge, less exposure to ADHD information, and less
frequent interactions with individuals with ADHD than their White counterparts (Table 2,
Bussing et al., 1998; 2003a; 2007; 2012; McLeod et al., 2007). White parents were more often
exposed to information about ADHD from physicians, medical journals, newspapers, other
written materials, hospitals and clinics, friends, teachers and schools, and the internet (Bussing et
al., 1998, 2007). Additionally, Bussing and colleagues (1998, 2007) found that African
Americans were more likely to receive information from the public health departments than
White parents (Table 2). These findings are important to MDM as individuals who know more
about ADHD may be more likely to have exposure to information about pharmacotherapy
options (Bussing et al., 1998).
Explanatory models of ADHD. Explanatory models of illness pertain to the individual’s
beliefs about the illness, the meaning of the illness, and the notions about the expected treatments
(Kleinman, 1980). Explanatory models of illness explore the perceptions of the cause of the
illness, how the illness started, how the illness affects the person, the severity of the illness, and
the type of treatment one should receive (Hark & DeLisser, 2009). In our literature review and
synthesis, the majority of the evidence on explanatory models of ADHD are based on the works
of Bussing and colleagues (Bussing et al., 1998, 2003a, 2007, 2012). Additionally, dosReis et al.,
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(2007), Graves (2017), Mychailyszyn et al. (2008), and Olaniyan et al. (2007) conducted
qualitative studies in which themes of explanatory model emerged. African American parents,
some of whom were caregivers to children with ADHD and some who were not, attributed
ADHD-like behaviors to origins other than medical or biological causes. Explanations of
ADHD-like behaviors included poor parenting, lack of attention, insufficient discipline, or a
normal stage of development that would be outgrown (Table 2, Bussing et al., 1998, 2003a,
2007, 2012; dosReis et al. 2007; Graves, 2017; Mychailszyn et al., 2008; Olaniyan et al., 2007).
Moreover, these beliefs were more common among African American than White parents. In
Bussing et al.’s (1998) study, African American caregivers were twice as likely to indicate that
ADHD is caused by eating too much sugar compared to White caregivers and more likely to
label their child as bad, while they were significantly less likely to attribute ADHD to genetic
origins, or apply a medical label (Table 2). Bussing and colleagues reported similar findings in
their subsequent studies (Bussing et al., 2003a, 2007, 2012). Some African American parents
expressed the belief that the diagnosis of ADHD was not real (Olaniyan, 2007). McLeod et al.
(2007) found that the odds ratio of endorsing ADHD as a real disorder among African
Americans was 0.52 (p < .05) compared to Whites.
Cultural differences in perceptions of ADHD. In their study, Bussing et al., (2003b)
found that White children had twice the odds of African American children to receive an
evaluation, diagnosis, or treatment for ADHD, despite the fact that there were no differences in
rates of recognition of ADHD symptoms (Table 2). They concluded that there may be cultural
differences in the threshold that determines when a parent seeks help for ADHD symptoms
(Bussing et al., 2003a). This notion has been supported in other studies. For example,
participants in Olaniyan et al.’s (2007) study expressed concern that ADHD represents a
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medicalization of typical behavior. Hillemeier et al. (2007) administered a commonly used
parent-rated ADHD diagnostic instrument to African American and White caregivers of children
with ADHD. They found that White caregivers reported more symptoms of hyperactivity than
their African American counterparts despite comparable levels of hyperactivity as rated by
teachers (Hillemeier et al., 2007). This indicates that hyperactivity is perceived differently
according to race. Their findings imply that children with similar underlying needs may receive
different medical treatment based on parent report of symptoms utilizing instruments that
function differently across populations (Hillemeier et al., 2007).
The Impact of Fundamental Perspectives on MDM in ADHD
Fundamental perspectives of ADHD, including knowledge, explanatory model, and
cultural norms, impact different areas in MDM. One area which is impacted is parental beliefs of
efficacy and effectiveness of ADHD medications. Bussing et al. (1998, 2007) reported that
significantly fewer African American parents believed medications can be effective in treating
ADHD than White parents (Table 2). The odds of an African American endorsing medication as
a treatment were 0.7 (p < .05) compared to White parents (Bussing et al., 2007). Bussing et al.
(2003b) found the only significant difference in barriers to care between groups was that African
American caregivers indicated they had a negative expectation for treatment, such as they
thought the treatment could not help, compared to Whites (Table 2). Similarly, Krain et al.
(2005) developed an instrument to assess treatment acceptability which pertains to the attitude
toward pharmacological treatment, and pursuit which refers to the choice to receive
pharmacological treatment. The instrument was administered to caregivers of children with
ADHD who had not been previously treated. They found that White caregivers rated medication
acceptability significantly higher than minority caregivers, and that 78.9% of White children
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went on to receive medication therapy, while only 27.3% of minority children did (Krain et al.,
2005).
The difference in certainty of efficacy of medical treatment may be due to differing
explanatory models. Preferences for medical treatment of ADHD are associated with a biological
explanatory model (Bussing et al., 1998, McLeod et al., 2007; Pham et al., 2010). Pham et al.,
(2010) assessed differences in parental beliefs about causes of ADHD among 119 ethnically
diverse parents of children with and without ADHD through their researcher-developed
instrument. They found that both beliefs of biological and behavioral causes of ADHD
significantly predicted medication treatment preferences (Pham et al., 2010). Endorsing a
biological cause for ADHD was associated with a preference for medication only treatment (p =
.037, Pham et al., 2010). Pham et al.’s (2010) conclusion was supported by dosReis et al.(2007),
McLeod et al.(2007), and Mychailyszyn et al. (2008). These findings demonstrate how important
perceptions of medication and explanatory model are to subsequent treatment decisions.
The second area in which fundamental perspectives of ADHD impact on MDM is an
amplified concern for side-effects of medications and addiction among African Americans.
African American individuals express greater concern for side effects of psychiatric medications
(p < .01, Schnittker, 2003). In ethnic minority samples, concerns for drug abuse, addiction,
sedation, and weight loss result in reserving medication as a last resort or refusing it entirely for
the treatment of ADHD (Berger-Jenkins et al., 2012; dosReis et al., 2006; Graves, 2017;
Olaniyan et al., 2010). dosReis et al. (2006) developed a survey based on existing evidence to
assess attitudes of African American caregivers whose children had recently taken a medication
for ADHD – about 17% were concerned about abusing the medication and 21% about unwanted
side-effects. Berger-Jenkins et al. (2012) and Graves (2017) identified concerns specific to
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Ritalin in minority parents of children with ADHD. Concerns included sedating side effects,
weight loss, and addiction and were sufficient enough that respondents reserved medication as a
last resort or refused entirely (Graves, 2017; Olaniyan et al., 2010). In their sample of 70
caregivers of minority children with ADHD, Berger-Jenkins et al. (2012) found that parents who
expressed concerns (i.e. weight loss and addiction) about medications were 2.5 times less likely
to use treatment at follow-up.
Finally, African American caregivers’ fundamental perspective of ADHD directly
impacts parental tolerance and perception of ADHD behaviors and symptoms. Studies revealed
that African American caregivers perceived ADHD behaviors and symptoms as typical
childhood behaviors, or that a child was “just bad” (Mychailyszyn et al., 2008). Similarly,
Bussing et al. (2003b) found that African American caregivers were less likely to recognize
ADHD behavioral symptoms as problematic or impairing compared to their White counterparts.
This may result in a decreased likelihood that African Americans will present to medical
professionals for a diagnosis of ADHD. Bussing et al. (2007) supported this notion, finding that
African American caregivers were less likely to have a child evaluated compared to their White
counterparts (51% vs. 28%). Moreover, variations in tolerance of ADHD symptoms based on
cultural norms may mean that children with similar underlying symptoms receive disparate
medical treatment due to utilization of instruments that are based on parental report of
symptoms. Hillemeier et al. (2007) demonstrated that standardized instruments perform
differently across ethnicities. For example, at the same level of hyperactivity, African American
caregivers are less likely to endorse items measuring hyperactivity than White parents
(Hillemeier et al., 2007). Thus, medications may not be offered to minority children based on
differences in caregiver report of symptoms. Furthermore, removing items from a standardized
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assessment of ADHD that perform differently between races can reduce medication disparities
(Hillemeier et al., 2007).
ADHD as a Form of Social Control
A final unique and important factor to ADHD MDM among African Americans is the
belief that ADHD diagnosis and treatment are attempts at social control. In a study of African
American parent perspectives of ADHD, Olaniyan et al. (2007) noted that participants felt the
diagnosis of ADHD represented a form of social control, as did use of medications to control
behaviors. ADHD was described as “something the medical people came up with to handle kids”
(Olaniyan et al., 2007, p. 228), so they “’just sit there like zombies’” (Table 2, Olaniyan et al.,
2007, p. 229). Participants in other studies indicated that they selected medication treatment only
as a result of pressure from a third party, typically the school system (Graves, 2017; dosReis et
al., 2007). Rather than using the term social control, dosReis et al., (2007) called this “coerced
conformance,” a phase of parental decision making with their children’s care in which they do
not see their children’s behaviors are problematic but yet are compelled to yield to their
children’s school coercion to opt for treatment.
Medications were viewed by African American parents as a mechanism to propagate
addiction (Table 2, Olaniyan et al., 2007). One participant’s quote clearly represents this theme:
“Because of addictions past and present and how much it really hurts the black community. I
think that’s another reason why we don’t like to consider using drugs” (Olaniyan et al., 2007, p.
229). Physicians were also perceived as colluding with pharmaceutical companies (Bussing et
al., 2003b). A lack of trust in healthcare professionals, in the diagnoses they render, and in the
treatments, they recommend contribute to MDM and subsequent pharmacotherapy disparities for
ADHD.
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Discussion
This literature synthesis demonstrates that culture exerts a strong influence on MDM in
African American caregivers of children with ADHD. Multiple factors converge to produce
persistent disparities in ADHD treatment. These include African American caregivers’
perspectives on typical childhood behavior and explanations for behavioral issues, the validity of
ADHD as a diagnosis, concerns about efficacy and safety of stimulant medications, mistrust in
physicians and the pharmaceutical industry, and views of ADHD diagnosis and treatment as
forms of social control, along with culturally biased ADHD screening tools. Moreover, a
blending of historical, structural, and political influences result in a preponderance of African
American families in lower socioeconomic status, and therefore vulnerable to disparities related
to access to care and segregation (Paidipati et al., 2017; Saloner et al., 2013). These findings
must be integrated into practice and research agendas to ensure equity in treatment of ADHD for
all children.
Implications for Practice
Clinicians can address culturally based ADHD treatment disparities by adopting a
patient-centered approach to ADHD management. Clinicians should explore beliefs, knowledge,
and misgivings regarding both the diagnosis and treatment of ADHD, in order to better provide
patient education, pursue acceptable forms of treatment, and promote shared decision-making
(Paidipati et al., 2013). Additionally, clinicians must be aware that initiation of a medication is
not a sufficient hallmark of treatment adoption. Continued relationships, assessment, and support
of African American children with ADHD and their caregivers are required to address disparities
in medication adherence and persistence. Finally, clinicians can use instruments that have been
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validated in diverse populations when screening for ADHD, such as the Terry and the Vanderbilt
ADHD scales (Flowers & McDougle, 2010).
In addition to individual clinician efforts, healthcare infrastructure and policy must adjust
to address ADHD treatment disparities. Establishing long-term partnerships in culturally relevant
community-based contexts may allow mental health establishments to build trust with the
African American community and identify and partner with highly-regarded change agents
(Jemmott, et al., 2017). Furthermore, education establishments will need to address barriers that
perpetuate the underrepresentation of African American physicians and members of the
psychology workforce (Lin et al., 2015; Prince & Williams, 2017). The work of policymakers
will be to ensure that neither race nor socioeconomic status, or their convergence, impede
children from receiving equitable treatment for ADHD.
Implications for Research
Though much has been published documenting disparities in ADHD treatment, our
literature synthesis demonstrates that gaps persist in knowledge needed to address medication
disparities. Further research is needed to explore how assessment and diagnostic tools for ADHD
are culturally sensitive and how established ADHD diagnostic rating scales are used and
administered in culturally diverse communities. Additionally, participatory research is needed to
determine if community-based interventions can overcome African American caregiver mistrust
in the medication establishment, and specific concerns related to ADHD as a form of social
control. The social control aspect specifically deserves greater attention from the medical
community as only Olaniyan et al., (2007) drew attention to it, though it is a deeply-rooted tenet
with hundreds of years of historical foundation (Johnson, 2013). Qualitative research exploring
perspectives of African American’s who have experienced the diagnosis and treatment of ADHD
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as a means to subjugate African American children is needed in order to understand the
contributions of social control to medication disparities, and potentially address them. Finally,
research to date has not sufficiently explored the complex processes that African American
families navigate when making decisions about medications for their children with ADHD.
Families continually make and revisit decisions as they attempt to gain knowledge, balance
behavior management with side-effects, and weigh other concerns related to ADHD medications
(Rashid et al., 2018a). Decision making does not happen only once as a medication is started, or
just once more as the medication is discontinued, but it is an ongoing process, particularly when
caregivers have to deal with medication-related decisions on a daily basis. How African
American families move through these medication decisions as a process is largely unknown.
Additionally, there has been very little description of what is supportive to MDM for African
American caregivers. MDM is a complex process that warrants further investigation as current
research has not addressed the nuances of the African American culture. MDM is a complex
process that warrants further research.
Conclusion
The purpose of this literature review was to elaborate the current understanding of
African American caregivers’ experiences of MDM for their children with ADHD. More work is
needed to understand MDM in African American caregivers of children with ADHD. Gaps
persist in understanding how African American caregivers’ perspectives on ADHD contribute to
decisions regarding medication treatment at each point in the process of MDM. Failure on the
part of the medical community to better understand and address the decisions of African
American’s related to ADHD treatment further perpetuates healthcare disparities. These
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disparities must be addressed to ensure that all children with ADHD receive comprehensive
treatment to succeed through their adolescence.
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Chapter 4: Manuscript 3
Medication Decision Making in African American Families of Children with ADHD: A Mixed
Methods Study
The final manuscript, a sequential exploratory mixed method study exploring factors
associated with MDM in low-income African American families of children with ADHD,
addresses gaps identified in Manuscript 2. During the first phase, seven low-income African
American caregivers of children with ADHD participated in semi-structured interviews focused
on their experiences with MDM. Qualitative analysis resulted in seven themes including child
safety and volatility, caregiver aggravation, caregiver mental health, sole caregiver status, receipt
of family centered care (FCC) and shared decision making (SDM), and school involvement.
These themes were validated through secondary analysis of data from a national sample of lowincome African American children with ADHD who participated in the National Survey of
Children’s Health (NSCH). Receipt of FCC, SDM and previous receipt of special education
services were independently associated with receipt of a medication for ADHD. Findings of this
study indicate that clinicians practicing FCC and SDM can impact health equity for African
American children with ADHD. Study results suggest that future research should focus on
development of interventions to promote FCC and SDM, and the evaluation of intervention
efficacy in achieving health equity.
Written permission was obtained from the manuscript co-authors to include this
manuscript in the dissertation (Appendix B & Appendix E). Furthermore, this manuscript is
currently under-review with the Journal of the American Academy of Child and Adolescent
Psychiatry (Appendix F), the leading peer reviewed journal focused on child and adolescent
psychiatry (Elsevier, 2021).
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Manuscript in Preparation, School of Nursing, University of Nevada, Las Vegas.

83

Abstract
Objective: Significant pharmacotherapy disparities exist for African American children with
attention-deficit/hyperactivity disorder (ADHD). Research on the factors contributing to
medication decision making among African American families of children with ADHD has not
been sufficient to inform interventions effective in reducing ADHD disparities. The purpose of
this study was to explore how and why some low-income African American caregivers seek
medical treatment for their children with ADHD. Method: This study utilized a sequential
exploratory mixed method. A preliminary qualitative phase (Phase 1) designed to identify
important variables to ADHD medication decision making was followed by a quantitative phase
(Phase 2) to validate the emergent framework and extract findings to a larger population. Phase 1
comprised a case study of seven low-income African American caregivers of children receiving
medication for ADHD who participated in semi-structured interviews. Phase 2 involved a
secondary analysis of data on African American uninsured or publicly insured children age 6-17
with ADHD (n = 450) from the National Survey of Children’s Health (NSCH). Results: Themes
identified through qualitative analysis included child safety and volatility, caregiver mental
health, caregiver aggravation, family centered care (FCC), shared decision making (SDM), sole
caregiver status, and school involvement. After adjusting for ADHD severity, previous receipt of
special education services and experiences of FCC and SDM were independently associated with
receipt of a medication for ADHD. Conclusion: Clinicians and school personnel can intervene to
decrease disparities in the treatment of ADHD.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the most common pediatric
neurobehavioral disorder in the United States (US), with approximately 8.4% of children
reporting a current diagnosis, and 9.4% reporting a diagnosis during their lifetime (Danielson et
al., 2018a). The core symptoms of ADHD include hyperactivity, impulsivity, and inattention.
These symptoms have negative impacts on academic, occupational, social, safety, and family
outcomes for individuals with ADHD (Laugesen et al, 2016; Shaw et al., 2012). Fortunately, the
core symptoms of ADHD are responsive to medication treatment (Wolraich et al., 2019).
Pharmacotherapy for ADHD is associated with improvements across ADHD outcomes (Shaw et
al., 2012). However, only about 62% of children with a current diagnosis of ADHD receive
medication (Danielson et al., 2018a). Caregiver hesitancy to adopt medication treatment for
children with ADHD has been related to non-physiologic explanation of ADHD symptoms,
influence of friends and family, influence of media and other informal information sources,
negative experiences of stigma, concerns for side effects, and fears of addiction and abuse
(Gajria et al., 2014; Rashid et al., 2018a; Ross et al., 2018; Taylor & Antshel, 2021).
While medication treatment of ADHD is not optimized overall, African American,
Hispanic, and other minority groups are significantly less likely to receive medication than White
children (Danielson et al., 2018a; Bax et al., 2019). While trends indicate diagnostic disparities
in African American children have reduced over time, medication treatment disparities have not
(Glasofer & Dingley, 2021). The persistently lower rates of medication treatment in minority
groups may have culturally specific origins which cannot be generalized across minorities. A
recent review identified unique considerations among African American caregivers including
fundamental perspectives of ADHD, norms for childhood behavior, and concerns that ADHD
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treatment is a form of social control (Glasofer et al., 2021). Furthermore, attentiondeficit/hyperactivity disorder (ADHD) is one pediatric mental health diagnosis in which both
ethnic and socio-economic treatment disparities exist (Cummings et al., 2017). There is a need to
explore within group variation in order to better connect race, socioeconomic status, and ADHD
medication treatment decisions among low-income African Americans and improve equity in
ADHD outcomes (Glasofer & Dingley, 2021; Sen & Waslow, 2016). Thus, the purpose of this
study was to explore how and why some low-income African American caregivers seek medical
treatment for their children with ADHD while others do not.
Methods
Design
This study utilized a sequential exploratory mixed method design (Creswell & Clark,
2011). In the current study, the key variables to measure regarding how and why some lowincome African American caregivers select medication for their children with ADHD were
initially unknown. Thus, a mixed method design with a preliminary qualitative phase (Phase 1)
designed to identify important variables to ADHD medication decision making was followed by
a quantitative phase (Phase 2) to validate the emergent framework and extract findings to a larger
population (Creswell & Clark, 2011). The qualitative phase utilized a multiple case study of lowincome African American caregivers of children receiving medication for ADHD following
Yin’s (2018) framework and resulted in thematic findings related to medication selection. Phase
2 involved a secondary analysis of a large public data set aimed to validate the relationships
between the themes described in the qualitative phase and medication selection among lowincome African American children with ADHD.
Sample and Data Source
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Participants for the qualitative phase of the study were recruited from an outpatient
pediatric behavioral health clinic in an urban setting in New Jersey. Caregivers were invited to
participate if they met the following inclusion criteria: (a) identified as African American , (b)
identified as a caregiver of a child age 6-17 with ADHD, (c) participated in decision making
regarding the medical ADHD treatment of the child, (d) the child was currently receiving a
medication for ADHD, and (e) the child was uninsured or on government insurance only
After completing Phase 1, existing databases were reviewed for alignment with the
themes resulting from the qualitative analysis. The National Survey of Children’s Health
(NSCH) was selected for triangulation of qualitative findings as most themes were represented in
selected items. The NSCH is a mail- or internet-based survey conducted by the U.S. Census
Bureau within the U.S. Department of Health and Human Services covering the 50 states and the
District of Columbia (Child and Adolescent Health Measurement Initiative, ND). The full NSCH
dataset, methodology, and procedures are publicly available at
https://www.childhealthdata.org/learn-about-the-nsch/NSCH. The survey collects information on
key indicators of health and well-being for children ages 0-17.The sample size required for this
phase of the study was 276 at a power level of 0.80 and alpha = 0.05. The NSCH datasets
collected from 2016-2017 and 2018-2019 were utilized. The analytical sample includes African
American children age 6-17 with a current diagnosis of ADHD who were uninsured or receiving
government subsidized insurance only. To compare children receiving a medication to those who
were not, children were included regardless of their ADHD medication status in Phase 2.
Data Collection and Measurement
After receiving institutional review board approval (Appendix G) to conduct the study,
the qualitative phase commenced. One investigator (AG) approached caregivers in the clinic

87

waiting room and distributed fliers. After providing informed consent, each interview was
preceded by collection of demographic data. Caregivers then participated in a semi-structured
interview with the purpose of understanding medication decision making for their children with
ADHD. Interviews were recorded, lasted approximately 1 hour, and were conducted in a private
location. A small gift certificate was provided to participants. All interviews were conducted by
the same investigator (AG). Interviews were conducted from February to March 2020.
For the quantitative phase, select items of the NSCH were utilized. The descriptive
variables included gender, age, insurance status (public insurance or unisured), and ADHD
severity (mild, moderate, or severe). The analytical sample included only those who had
responded uninsured or public insured only. The dependent variable for this study was whether
currently receiving a medication for ADHD. For this variable, participants were only included in
the analytical sample if they had endorsed a current diagnosis of ADHD.
For independent variables, each qualitative theme was mapped to NSCH items that best
operationalized the theme. The investigators reviewed the themes, potential items, item scoring,
and hypotheses until there was agreement on item selection and scoring. Ultimately, the
independent variables included neighborhood safety, school safety, child volatility, a safety and
volatility composite score, caregiver aggravation, caregiver mental health, family centered care
(FCC), shared-decision making (SDM), receipt of special education services, and contact by the
school for problems at school. Table 3 presents each theme and the associated NSCH items as
well as information regarding item scoring. Volatility was an author derived composite including
items that reflected behaviors that Phase 1 participants described potentially leading to unsafe
situations. The child safety and volatility composite, also author derived, added parent perception
of child safety in the neighborhood and school to the volatility composite. Caregiver mental
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health was assessed for both the caregiver responding to the survey (Caregiver 1), and an author derived composite of combined
caregiver 1 and 2 mental health. The composite scores for parent aggravation, FCC, and SDM are original to the NSCH scoring
system. All other variables consist of individual items from the NSCH.

Table 3
Phase 1 Qualitative Themes with Corresponding Phase 2 NSCH Database Items
Theme
Child Safety
& Volatility

Variable
Name
Neighborhood
Safety

NSCH Items
This child is safe in
our neighborhood

School Safety

This child is safe at
school

Volatility
Composite

This child stays calm
and in control when
faced with a
challenge
This child argues too
much

2016-2017
Scoring
4-Point scale
from
definitely
agree to
definitely
disagree
Point scale
from
definitely
agree to
definitely
disagree
3-point scale
from not
true to
definitely
true
3-point scale
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2018-2019
Scoring

4-point
scale
from
never to
always
4-point
scale

Transformations

2018-2019
converted to
usually or
always =
definitely true,
sometimes =

Final Scoring

Composite score
ranged from 3-9
with a higher
score reflecting
greater volatility

Theme

Variable
Name

NSCH Items

This child bullies
others, picks on
them, or excludes
them

2016-2017
Scoring
from not
true to
definitely
true
3-point scale
from not
true to
definitely
true

2018-2019
Scoring
from
never to
always

Transformations

5-point
scale
from
never to
almost
every day

2018-2019
converted to
never or 1-2
times per year =
not true, 1-2
times per month
= somewhat
true, 1-2 times
per week or
almost every
day = definitely
true

somewhat true,
never = not true

Safety &
Volatility
Composite

Caregiver
Mental
Health

Caregiver 1
Mental
Health
Caregiver 2
Mental
Health

Final Scoring

Total score of all
items in child
safety & volatility
composite
ranging from 517
In general, how is
your
mental or emotional
health?
In general, how is
Caregiver 2’s
mental or emotional
health

5-point scale
from
excellent to
poor
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Individual
responses were
collapsed to two
categories:
good, very
good, or
excellent =
good; poor or
fair = not good

Theme

Variable
Name
Composite
Mental
Health

NSCH Items

2016-2017
Scoring

Caregiver
Parent
During the past
Aggravation
Aggravation
month, how often
have you felt:

FCC

FCC

This child is much
harder to care for
than most children
of his or her age?

5-point scale
from never
to always

This child does things
that really bother
you a lot?

5-point scale
from never
to always

Angry with this child?

5-point scale
from never
to always

If this child has had a
healthcare visit in
the past 12 months,
how often did the
child’s doctor or

2018-2019
Scoring

Transformations

Final Scoring
Couples in which
both caregivers
rated mental
health as good =
good; couples in
which one
caregiver mental
health as poor =
not good
If parent responded
usually/always to
one or more item
in composite =
parent
usually/always
aggravated from
parenting; if no
response of
usually/always =
parent seldom
feels aggravation
from parenting

If parent responded
never/sometimes
to one or more
item in composite
= did not receive
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Theme

Variable
Name

NSCH Items

2016-2017
Scoring

other health care
providers:
Spend enough time
with this child?

4-point scale
from
always to
never
Listen to you
4-point scale
carefully?
from
always to
never
Show sensitivity to
4-point scale
your family’s values
from
and customs?
always to
never
Provide the specific
4-point scale
information you
from
needed concerning
always to
this child?
never
Help you feel like a
partner in this
child’s care?
SDM

SDM

2018-2019
Scoring

Transformations

Final Scoring
FCC; if no
response of
never/sometimes
in composite =
received FCC

4-point scale
from
always to
never

If this child needed
decisions made
regarding health
care, such as
whether to get
prescriptions,
referrals, or

If parent responded
never/sometimes
to one or more
item in composite
= families
never/sometimes
feel that they are
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Theme

Variable
Name

NSCH Items

2016-2017
Scoring

procedures, how
often did the child’s
doctors or other
health care
providers:

Sole
Caregiver
Status

Discuss with you the
range of options to
consider for his or
her health care or
treatment?

4-point scale
from
always to
never

Make it easy for you
to raise concerns or
disagree with
recommendations
for this child’s
health care?

4-point scale
from
always to
never

Work with you to
decide together
which health care
and treatment
choices would be
best for this child?
Caregiver 2
How is Caregiver 2
Relationship
related to this child?
to Child

2018-2019
Scoring

Transformations

Final Scoring
partners in
decision making;
if no response of
never/sometimes
in composite =
families usually
or always feel
that they are
partners in
decision making

4-point scale
from
always to
never

Seven options
including
there is only
one primary
adult
caregiver in
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One primary
caregiver = sole
caregiver; all
other responses =
partnered
caregiver

Theme

Variable
Name

School
Special
Involvement
Education
Services

NSCH Items

A: Has this child ever
had an early
intervention or

2016-2017
Scoring
the
household
for this
child
Yes or No

special education
plan?

2018-2019
Scoring

Transformations

Final Scoring

If no to A = Never;
If yes to A and B
= Current; If yes
to A and no to B
= Previous

B: Is this child
Yes or No
currently receiving
services under one
of these plans
Contact for
During the past 12
3-point scale
problems at
months, how many
from none
school
times has the child’s
to 2 or more
school contacted
times
you or another adult
in your household
about any problems
he or she is having
with school?
Note. FCC = Family Centered Care; SDM = Shared Decision Making
Data Analysis
Analysis for Phase 1 of the study followed Yin’s (2018) framework. Interviews were digitally audio-recorded and transcribed.
Each interview was analyzed as a whole. Coding was conducted and discussed between investigators to identify potential themes,
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revisions to ideas, and appropriate lines of inquiry for subsequent interviews. Cross-case
synthesis was conducted to identify themes across cases (Yin, 2018). Discussion and review of
the transcripts, codes, and themes continued until consensus was reached, with illustrative quotes
identified for each theme.
For Phase 2 all analyses were performed with SPSS version 28. Demographic data were
analyzed using descriptive statistics and frequency tables. Univariate logistic regression was
conducted with each independent variable to determine if there was an association with
medication receipt in the NSCH sample. Multivariate regression was subsequently conducted
with all variables that were significant at the level of p < .05 in the univariate analyses. One
additional variable significance was included. FCC and SDM were excluded from multivariate
regression as their Ns were significantly smaller than the analytical sample size. Demographic
variables were also tested for association with medication receipt and included in multivariate
analysis as a covariate if significant. A p-value of  .05 was considered statistically significant.
Results
Phase 1
Seven individuals participated in six interviews for the qualitative portion of this study as
one interview was conducted with a couple. There were five female participants and two male
participants. Caregivers ranged in age from 30 to 63. All of the eight children discussed were
male, and ranged in age from 6-17. They were all covered by a Medicaid plan. The mother and
grandmother of two brothers were interviewed separately, one participant discussed both his
nephew and stepson, and participants in four interviews discussed siblings with ADHD. Seven
themes were identified in relation to medication receipt in children with ADHD of low income
African American caregivers, including child safety and volatility, caregiver mental health,
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caregiver aggravation, FCC, SDM, sole caregiver status, and school involvement. Table 4
presents these themes and illustrative quotes.

Table 4
Qualitative Themes and Illustrative Quotes
Theme
The Child’s Safety &
Potential for
Violence

Caregiver Aggravation

Caregiver Mental
Health
Family Centered Care

Illustrative Quotes
“No one wants to put their child on medication. But sometimes if
you don't, you might raise a murderer. I don't know. So I'm just
trying to keep him safe, and me too.”
“Once he started taking the pills, all the lashing out stopped and
trouble stopped, fights and all that stopped. But if you don't take
it, I'm scared something going to happen.”
“It's like something bad going to happen him if he keep going to
messing with people, bullying people. Or one day, he might go
out on the street, mess with somebody, calling people wrong
names. They might kill him or beat him up or anything could
happen to him. I mean I don't want nothing to happen to my son.”
“He doesn't want to hear what I got to say. He don't want to hear my
talks, my speeches, my lectures. He want to go play on his phone.
I don't know what to do.”
“His hygiene's is really bad, he forgets to take showers. I have to say
A, did you take a shower? He say, I can't remember mom. And I
thought he was joking at first. He's really serious. He really can't
remember. He forgets to wash his clothes, so I have to make sure
he puts it in the dryer. I constantly redirect him so many times on
a daily basis.”
“So I just got to keep emphasizing to him in the morning: "you can't
talk on the phone, you got to eat, you got to take your meds, you
got to clean your room in the morning, make your bed. Brush your
teeth, wash your face, keep dressed and then get on the phone." I
just got to keep constantly, every morning. Like I said.”
“But I already knew how to deal with him with that behavior and
that diagnosis because I was diagnosed with it. I already know
about Adderall, Zoloft, Concerta, Metadate, and Ritalin.”
“No one listens. They listen, but it’s like going in one ear and out
the other… I don’t think they had the patience to sit here like
you’re sitting in here now to hear what I really have to say.
They’re trying to get back to the next patient.”
“First of all, they said this girl can’t read or write, she don’t know
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Shared Decision
Making

Sole Caregiver Status

what she’s talking about, she’s not a professional. So I believe I
was judged.”
“They should listen to when people are crying out. They should
listen because people is not crying out just to be crying out. They
really need your help. For the people who didn’t help me, I
definitely needed your help…I think if they would have helped
me when I was crying out, it wouldn’t be this deep.”
“I wish they knew that if they study ADHD children along with the
medicine that they give them, and when a parent says not working
for them to look more into it”.
“They want to try to change up your regimen on how you do things,
or they think they know more than what you know because you’re
the parent and they’re the nurse, so evidently they went to school
for things like that. So they apparently think that you’re not
capable of knowing when your child’s supposed to take the meds
or how the meds are supposed to be given.”
“The reason why I didn’t give it to him like that because like he
sitting there talking, ‘Oh he need pills’… ‘Oh, you need pills’.
How do you know you need pills if you don’t do no test or try to
find out? So I didn’t give it to him.”
“He doesn’t like it but he has no choice because I’m the sole
custodial parent. What I say goes.”
“Most of the people, they know like why he on pills. They don’t
want me to give him the pills. Now I’ve got to hear that in my ear.
Oh, nobody be there for me. I’m the one doing this, taking these
kids by myself. Taking care of these kids by myself and no one
else with the dad or nobody.”
“When anybody start helping me with the kids and see how they act
24/7, then you’ve got a say so, but until then I know I have them.”

School Involvement
“The schools need to learn how to better handle these kids and not
isolate them and put them in this one classroom. With actual kids
that do have problems on learning…They put the kids that has the
learning disabilities with the kids that have the mental health…So
then that's when the behavior comes in, because they're not being
challenged on that work, because they got them in there with the
kids that already have a learning disability, but they don't have a
learning disability.”
“The school had a problem with it. So they diagnosed... they had to
do a psych eval first”
“That school, It was like every day I was going up there for him.”
“Then he was always getting sent home. The school used to call me
to pick [him] up. Always going to the Dean's. To the point like
last year, he didn't get nothing done in school because he was
coming home more than he was in school.”
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Two of the themes related to the child’s behavior, included safety and volatility, and
caregiver aggravation. The child’s safety was frequently discussed by participants, as was the
safety of others. Caregivers expressed concerns that the child’s volatility and impulsivity might
lead him to say or do something that would cause others to act violently against him. They were
also fearful that the child could act violently against others, including the caregivers themselves
or others in the home, and that the child’s actions may ultimately result in involvement with the
criminal justice system. The theme of caregiver aggravation related to experiences of frustration
with the child’s inattention, oppositional and off-task behaviors, and overall burden of caring for
a child with ADHD. Participants described initiating medication as a means to keep their
children and others safe, and to decrease oppositional and off task behaviors. Caregivers believed
that medications were helping with impulsivity, and felt that maintaining a medication regimen
was important to future safety; however, they expressed continued frustration with oppositional
relationships and having to keep children on task.
Caregiver experiences with both medical and school systems shaped medication decision
making for their children with ADHD. Participants felt clinicians had at times included them in
decision making, while other times they had unilaterally made treatment decisions without
consulting the caregiver or considering their individual needs. Some caregivers described feeling
dismissed because they believed clinicians perceived them as uneducated. For these participants,
being included in decision making and seen as an individual was important to agreeing to
medication treatment for their children, while feeling dismissed led to feelings of indecision and
mistrust. When caregivers felt their child’s needs were not being met, they were persistent in
seeking other resources for treatment. Caregivers also described both positive and negative
experiences with schools. They expressed frustration that their days were frequently disrupted by
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calls from school, and feeling that the child’s behavioral needs were misinterpreted as lower
intelligence. Conversely, they described appreciation to the schools for identifying the need for
treatment, and for partnering in identifying when medications had been missed or administering
medications during school hours.
The final themes related directly to the caregivers’ life experiences and the influence of
family. The theme of caregiver mental health encompassed caregivers’ own mental health and
history with medications for behavior health diagnoses and that of their family members. All of
the caregivers interviewed were themselves on a medication for a psychiatric diagnosis, or had a
spouse, sibling, or parent who was being treated. They all described favorable past experiences
with psychoactive medications, and expressed that this supported their decision to use
medication to treat their child’s ADHD. Sole parent status comprised experiences specific to
single parents and medication decision making. While participants who were single parents
discussed consulting with family, they expressed that the decision to medicate rested solely with
themselves. They associated feelings of being alone in dealing with the challenges of parenting a
child with ADHD with a right to independence in making decisions regarding treatment.
Phase 2
After limiting the NSCH database to African American children age 6-17 with a current
diagnosis of ADHD who were uninsured or on public insurance and had data available for the
outcome variable (currently receiving a medication for ADHD), the final sample size was 450.
Overall, 69.1 % (n = 311) of the sample was currently receiving a medication for ADHD. Table
5 presents characteristics of the study sample. The only demographic variable associated with
medication status was ADHD severity. Children with moderate and severe ADHD were more
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likely to be receiving medication than children with mild ADHD, 2(2, n = 438) = 25.46, p
<.001.

Table 5
Descriptive Statistics
Characteristic

Phase 2
Total
(n=450)

Phase 2
Currently Taking
ADHD Medication
(n=311)

n(%)

n(%)

Phase 2
Not Currently
Taking ADHD
Medication
(n=139)
n(%)

114(25.3)
179(39.8)
157(34.9)

78(68.4)
137(76.5)
96(61.1)

36(31.6)
42(23.5)
61(38.9)

319(70.9)
131(29.1)

225(70.5)
86(65.6)

94(29.5)
45(34.3)

44(9.8)
406(90.2)

26(59.1)
285(70.2)

18(40.9)
121(29.8)

130(29.7)
200(45.7)
108(24.7)
8.42 ± 1.97*

71(54.6)
136(68.0)
92(85.2)
8.39 ± 1.90*

59(45.4)
64(32.0)
16(14.8)
8.48± 2.12*

5.29 ± 1.44*

5.37 ± 1.45*

5.12 ± 1.43*

215(48.6)
172(38.9)
33(7.5)
22(5.0)

159(74.0)
114(66.3)
19(57.6)
13(59.1)

56(26.0)
58(33.7)
14(42.4)
9(40.9)

262(60.1)
142(32.6)
24(5.5)
8(1.8)

190(72.5)
88(62.0)
15(62.5)
6(75.0)

72(27.5)
54(38.0)
9(37.5)
2(25.0)

Age, y
6-9
10-13
14-17
Sex
Male
Female
Insurance Status
Uninsured
Public Insurance
ADHD Severity
Mild
Moderate
Severe
Safety & Volatility
Composite Score
Volatility Composite Score
Safety in Neighborhood
Definitely Safe
Somewhat Safe
Somewhat Unsafe
Definitely Unsafe
Safety in School
Definitely Safe
Somewhat Safe
Somewhat Unsafe
Definitely Unsafe
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Caregiver 1 Mental Health
Good
372(84.2)
266(71.5)
106(28.5)
Not Good
70(15.8)
46(65.7)
24(34.3)
Caregiver 2 Mental Health
Good
340(81.0)
243(71.5)
97(28.5)
Not Good
80(19.0)
46(57.5)
34(42.5)
Parent Aggravation
Aggravated
110(24.6)
75(68.2)
35(31.8)
Not Aggravated
338(75.4)
235(69.5)
103(30.5)
Sole Caregiver Status
Sole Caregiver
215(50.4)
147(68.4)
68(31.6)
Partnered Caregiver
212(49.6)
147(69.3)
65(30.7)
Special Education Services
Never
46(10.4)
26(56.5)
20(43.5)
Current
233(52.7)
155(66.5)
78(33.5)
Previous
163(36.9)
122(74.8)
41(25.2)
Contact by school in last 12
months
None
98(22.4)
58(59.2)
40(40.8)
1
75(17.1)
50(66.7)
25(33.3)
265(60.5)
192(72.5)
73(27.5)
2
Family Centered Care
Yes
297(77.1)
218(73.4)
79(26.6)
No
88(22.9)
49(55.7)
39(44.3)
Shared Decision Making
Yes
135(79.4)
104(77.0)
31(23.0)
No
35(20.6)
20(57.1)
15(42.9)
Note. Total number of subjects varies for each variable due to the missing value. * Mean ±
standard deviation

The results of the univariate and multivariate logistic regressions are presented in Table
6. Figure 4 depicts the hypothesized and final study models. In univariate analysis, safety and
volatility, parent aggravation, and sole caregiver status were not significantly related to taking a
medication for ADHD. Variables with statistically significant or borderline significant
associations with taking a medication on univariate analyses were included in multivariate
logistic regression. These variables included safety in neighborhood, safety in school, caregiver
mental health, receipt of special education services, and contact by school regarding problems
with school. The regression model was statistically significant, 2(12, n = 389) = 28.27, p =
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.005. The model explained 9.8% (Nagelkerke’s R2) of the variation in ADHD medication
treatment. After accounting for ADHD severity, the model was statistically significant 2(14, n =
389) = 50.382, p = .001, and explained 16.9% (Nagelkerke’s R2) of variation in ADHD
medication treatment. In multiple regression, safety in school and neighborhood, and caregiver
mental health were not associated with taking a medication. Children of caregivers who had been
contacted by the school for problems in school more than once in the past year were twice as
likely to be taking a medication than children whose parents had never been contacted (OR =
2.20, 95% CI [1.28-3.78]). However, this relationship was no longer significant after accounting
for ADHD severity. Children who previously received special education services were more than
twice as likely to be treated with a medication than those who never received services (OR =
2.61, 95% CI [1.23, 5.52], after accounting for ADHD severity (AOR = 2.86, 95% CI [1.316.22]).
Because FCC was only measured in individuals who had experienced a medical visit in the past
year, and SDM was only measured in individuals who had made a medical decision in the past
year, their sample sizes were smaller than other variables measured (FCC n = 374; SDM n =
165). Therefore, FCC and SDM were not included in multivariate regression analysis. In
univariate analysis, children from caregivers who experienced FCC were twice as likely (OR =
2.20, 95% CI [1.34, 3.60]) to be taking a medication than those without this experience.
Similarly, children from caregivers who experienced SDM were more than twice as likely (OR =
2.52, 95% CI [1.15, 5.49]) to be taking a medication. Both relationships remained significant
after accounting for ADHD severity (FCC AOR = 2.78, 95% CI [1.64, 4.73]; SDM AOR = 3.26,
95% CI [1.42, 7.50]).
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Table 6
Factors Associated with Medication Taking by Univariate and Multivariate Analysis
Univariate Analysis
Related Theme
Variable
Safety & Volatility Safety & Volatility
Composite
Volatility Composite
Safety in Neighborhood
Definitely Safe
Somewhat Safe
Somewhat Unsafe
Definitely Unsafe
Safety in School
Definitely Safe
Somewhat Safe
Somewhat Unsafe
Definitely Unsafe
Caregiver Mental
Caregiver 1 Mental
Health
Health
Good
Not Good
Caregiver Composite
Mental Health
Good
Not Good
Caregiver
Aggravation
Aggravated
Not Aggravated

Multivariate
Analysis
OR(95% CI)
P

OR(95% CI)
0.98(0.88-1.08)

P
.664

1.13(0.98-1.31)

.093

Reference
0.69(0.45-1.07)
0.48(0.23-1.11)
0.51(0.21-1.26)

.101
.055
.142

Reference
0.78(0.47-1.30)
0.74(0.29-1.87)
0.76(0.25-2.30)

.337
.524
.630

Reference
0.72(0.42-1.22)
0.62(0.24-1.62)
0.78(0.24-2.52)

.221
.331
.682

Reference
0.62(0.40-0.95)
0.63(0.27-1.51)
1.14(0.22-5.76)

.030
.300
.877

Reference
0.66(0.39-1.10)
0.87(0.31-2.46)
1.21(0.20-7.40)

.112
.795
.836

Reference
0.71(0.42-1.21)
0.87(0.30-2.52)
0.84(0.12-5.84)

.210
.797
.860

Reference
0.53(0.32-0.90)

.018

Reference
0.63(0.17-2.27)

.479

Reference
0.48(0.13-1.78)

.272

Reference
0.54(0.33-0.89)

.016

Reference
0.64(0.20-2.11)

.466

Reference
0.74(0.22-2.46)

.623

Reference
1.07(0.67-1.69)

.791
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AOR(95% CI)

P

Sole Caregiver
Status

School
Involvement

Sole Caregiver
Partnered
Caregiver
Special Education
Services
Never
Current
Previous
Contact by school in last
12 months
None
1
2

Reference
1.05(0.69-1.58)

.829

Reference
1.53(0.80-2.91)
2.29(1.16-4.53)

.196
.017

Reference
1.46(0.73-2.94)
2.61(1.23-5.52)

.286
.012

Reference
1.47(0.71-3.03)
2.86(1.31-6.22)

.300
.008

Reference
1.38(0.74-2.58)
1.81(1.12-2.95)

.315
.016

Reference
1.47(0.73-2.93)
2.20(1.28-3.78)

.280
.004

Reference
1.40(0.69-2.86)
1.48(0.83-2.64)

.356
.183

Reference
2.20(1.34-3.60)

.002

-

2.78(1.64-4.73)

<.00
1

.020

-

3.26(1.42-7.50)

.005

Family Centered
Care
No
Yes
Shared Decision
Making
No
Reference
Yes
2.52(1.15-5.49)
Note. AOR = Odds Ratios adjusted for ADHD severity
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Figure 4
Hypothesized and Final Study Models

Note. FCC = Family Centered Care; SDM = Shared Decision Making
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Discussion
The results of this study validated through qualitative and quantitative methods that
experiences with healthcare providers and schools are key to medication decision making in lowincome African American families of children with ADHD. Moreover, as clinicians are
responsible for determining ADHD severity, the significance of ADHD severity as a covariate
highlights the role of clinicians in influencing which children receive medication for ADHD.
Although the quantitative results did not substantiate the relationships between taking a
medication for ADHD and caregiver mental health, child safety and volatility, or sole caregiver
status, these topics warrant further discussion.
Concerning experiences with healthcare providers, caregiver report of experiencing FCC
and SDM were associated with medication treatment for ADHD in both phases of this study.
Conversely, experiences of being dismissed or excluded from decision making were met with
indecision regarding selection of medication in case study participants. While the significance of
FCC in ADHD treatment outcomes have previously been noted, the findings of this study
highlight the importance of these experiences in an underserved demographic (Hinojosa et al.,
2012; Hogue et al., 2016). Though more than 75% of the sample in the quantitative portion of
this study endorsed experiencing FCC; previous research has identified that families of poor,
uninsured, and minority children with special health care needs are less likely to experience FCC
and SDM, as are children with ADHD compared to those with medical diagnoses (Butler et al.,
2015; Coker et al., 2010; Denboba et al., 2006). Specifically, in African American families of
children with special healthcare needs, disparities in time spent with the physician and sensitivity
to family values and customs have been identified (Coker et al., 2010). Clinicians must recognize
that the application of their expertise in concert with FCC and SDM can ensure that the most
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vulnerable children receive evidence-based treatment for ADHD. When practicing FCC and
SDM, clinicians should consider the customs and values known to influence medication decision
making in African American caregivers, including caregiver perspectives on norms for childhood
behavior, explanatory model for ADHD, previous knowledge of ADHD, and experiences of
ADHD as a form of social control (Glasofer et al., 2021). Future research should develop and
test interventions to increase clinician capability, motivation, and opportunity to engage in SDM
(Boland et al., 2019; Hayes et al., 2019).
The association between school systems and taking a medication for ADHD in lowincome African American children was made explicit by participants of the qualitative phase of
this study, and in part validated by the quantitative analysis. Receipt of special education services
is evidently important to taking a medication for ADHD in low-income African American
children. Interestingly, previous receipt of special services was associated with medication
treatment while current services was not. The cross-sectional nature of this study makes it
difficult to determine the reasons for this finding. Though the exact nature of the relationship
between receiving special education services and taking a medication for ADHD cannot be
determined based on these results, it is evident that special education programs can influence
ADHD treatment.
Conversely, calls to home regarding school performance was not independently
associated with medication taking. However, it remains an important experience for caregivers in
the studied population. Over 60% of the NSCH sample had received two or more phone calls in
the past year. This is in stark contrast to only 10% of families in the overall 2019 NSCH database
receiving two or more calls. Qualitative participants spoke about the stress that these phone calls
can cause, interrupting their workdays, and leaving caregivers feeling that they are responsible to
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solve school problems. The content and frequency of these phone calls may reflect the more
pervasive problem of disparities in school disciplinary outcomes, including higher rates of
disciplinary referrals, corporal punishment, suspensions, and inconsistent application of
sanctions for African American children (Welsh & Little, 2018). These findings suggest that
school personnel can act to widen ADHD treatment disparities, or advance healthcare equity for
African American children with ADHD. While schools are known to be as a major source of
referral for medical treatment of ADHD (Arya et al., 2015; Sax & Kautz, 2003), the findings of
this study emphasize the role of the school specific to low-income African American children
with ADHD. Future research should explore the nature of communication between teachers and
caregivers of African American children with ADHD. Additionally, research is needed to
understand the temporal relationship between medication treatment and exit from special
education services noted in this study. Interventions should focus on supporting teachers to
partner with African American caregivers of children with ADHD, and developing partnerships
between school districts and medical providers to ensure appropriate referrals for ADHD care
and improve access to care for vulnerable populations.
Though the themes of caregiver mental health, child safety and volatility, and sole
caregiver status related to medication taking in the qualitative results of this study, the
relationships were not confirmed in quantitative analysis. Various reasons exist for the absence
of positive findings. For caregiver mental health, the absence of significant findings likely reflect
a poor fit between theme content and NSCH items. Specifically, caregivers discussed the
relationship between their own experiences with medications for behavioral health diagnoses and
the choice to select medication for their children with ADHD. The NSCH items most closely
related to this asked about caregiver mental health, but did not ask about caregiver medications.
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Given that ADHD is highly heritable (Larsson et al., 2014), with nearly half of children with
ADHD having a parent with ADHD (Starck et al., 2016), the relationship between caregiver
mental health and medication taking and child receipt of medication should be further
investigated. Additionally, there is potential for clinicians to explore parental experiences with
medication for ADHD and other behavioral health diagnoses, and incorporate this in medication
decision making.
Measurement issues as well as sampling considerations may have contributed to the
absence of quantitative findings for child safety and volatility. In qualitative interviews,
participants made a direct connection between concerns for the child’s safety and volatility and
their decisions to initiate and maintain children on ADHD medications. All of the Phase 1
participants were drawn from an urban area in southern New Jersey that is historically rated as
one of the most dangerous cities in the US (Schiller, 2021). In contrast only 5% of the
quantitative sample rated their child as definitely unsafe in the neighborhood and less than 2%
definitely unsafe at school. It is unclear if this is a true reflection of the safety of African
American children living in poverty, or undersampling in families living in unsafe
neighborhoods. Moreover, the rating of neighborhood and school safety may be subjective, as
individuals living in different settings may have differing definitions of safety. Regardless, the
low proportion of respondents perceiving unsafe conditions for their children limits conclusions
that can be drawn about the relationship between child safety and being on a medication for
ADHD.
Unlike child safety and volatility, the theoretical relationship between parent aggravation
and ADHD medication treatment was tenuous based on Phase 1 interviews. Though aggravation
was frequently expressed by participants, including frustration with hyperactive, impulsive, and
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off-task behaviors, they also expressed tolerance for these behaviors. Caregivers hoped that
medications would help with hyperactivity, but noted little change. Some caregivers allowed for
medication vacations when the child was not in school, or remained unsure that these behaviors
required treatment. Quantitative analysis confirmed that parent aggravation is not associated with
medication treatment in this population. This finding is consistent with previous research
exploring norms for childhood behavior in African American caregivers. Using a standardized
instrument, Hillemeier et al. (2007) found that at the same level of hyperactivity, White parents
were more likely to endorse hyperactive behaviors than African American parents. DosReis et al.
(2007) found that African American caregivers selected treatment for their children with ADHD
as a result of third party intervention rather than their own concerns for behavior. This finding
again underscores the significance of outside influences, like schools and healthcare providers, in
medication decision making among low-income African American caregivers of children with
ADHD. It also highlights the importance of the need to explore individual customs and values as
considerations when engaging in shared decision making.
The final finding of the qualitative analysis was the relationship between being a sole
caregiver of a child with ADHD and medication treatment. Interview participants who were sole
caregivers spoke of the burdens of being the only parent responsible to meet the demands of
parenting a child with ADHD, and how this justified their choice to initiate medication treatment.
However, the quantitative analysis did not confirm this relationship. It is likely that this
commonality in the Phase 1 sample reflects additional influences. For example, the fact that
caregivers presented to a medical setting may indicate that they were more likely to adopt a
biological explanatory model for ADHD, which is associated with selection of medication
treatment (Pham et al., 2010). Though not necessarily related to medication decision making,
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clinicians should explore the resources and supports available to sole caregivers of children with
ADHD.
Regarding limitations of our study, the nature of qualitative research and the small
sample size present opportunity for bias and limit generalizability of findings. Multiple methods
of triangulation were utilized to address these concerns (Patton, 2015). Data sources were
triangulated through inclusion of multiple cases to incorporate varying perspectives. Investigator
triangulation allowed for multiple observations, conclusions, and confirmation of findings.
Finally, methodological triangulation through conduct of a sequential quantitative phase sought
to confirm whether the perspectives of the qualitative sample were shared by a broader sample,
and to allow for generalizability (Patton, 2015).
The quantitative phase of this study has limitations as well. The NSCH was selected as
items provided the best available match to themes identified in the qualitative phase. However,
survey items were not an exact representation of qualitative findings. Future instrument
development may be necessary to better measure factors associated with medication decision
making in diverse populations. The overall NSCH response rate ranged between 37.4-42.2% for
the included years; however, the response rate in the target demographic for this study is not
known. A low response rate may have led to a biased sample. Additionally, it is possible that
caregiver responses were biased related to poor recall or stigma. If so, the prevalence of taking a
medication for ADHD reported may not be accurate. Moreover, there is a lack of specificity
regarding medication treatment. Consequently, we were unable to report on types of
medications, doses, duration of therapy, or consistency in taking medications as prescribed and
cannot estimate medication treatment quality. As demonstrated in the qualitative findings of this
study, medication decision making is a dynamic process. While the quantitative findings offer
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some insight into the factors associated with medication taking in low-income African American
children with ADHD, they leave gaps in our understanding of how medication decision are made
over time.
To conclude, the present study explored medication decision making in low-income
African American caregivers of children with ADHD, and tested qualitative findings in a
sequential quantitative analysis. Qualitative findings indicated that child volatility and safety,
caregiver mental health experiences, caregiver aggravation, sole caregiver status, experiences of
FCC and SDM, and experiences with school intervention would be associated with the decision
to select medication treatment. In quantitative analysis, only previous receipt of special education
services, as well as experiences of SDM and FCC were independently associated with current
receipt of a medication after accounting for ADHD severity. Critically, these findings indicate
that clinicians and school personnel can intervene to decrease disparities in the treatment of
ADHD. Moreover, there are variations within minority groups that must be understood and
addressed in order to improve healthcare equity. Finally, medication decision making needs to be
understood as a process. Measures of treatment quality including medication type, dose,
treatment duration, and consistency in taking recommended treatment regimens need to be the
standard reported outcomes rather than simplistic measures of ADHD medication treatment
prevalence in order to truly address ADHD treatment equity.
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Chapter 5: Summary and Discussion
In this chapter, a summary is provided for the study that was conducted, including
findings, strengths, and limitations. The implications of the findings to healthcare education and
practice are articulated. Furthermore, suggestions for future research are included.
Summary of the Study
This study was comprised of three manuscripts that focused on understanding ADHD
medication treatment disparities in African American children. The first manuscript was a
literature review of ADHD diagnostic and medication treatment disparities in African American
children. The findings established the foundation for further exploration of reasons for ADHD
treatment disparities in this population. The second manuscript was a review of the literature on
MDM in African American caregivers of children with ADHD. Based on the findings of this
review, gaps were identified requiring further research before meaningful interventions can be
implemented to narrow medication treatment disparities. The third manuscript reported results of
a sequential exploratory mixed method study exploring how and why some low-income African
American caregivers select medication for their children with ADHD, and testing the proposed
framework. The institutional review boards (IRBs) of the University of Nevada, Las Vegas and
the recruitment site (Virtua Health) granted permission to conduct the mixed method study.
Findings
In the first manuscript, a review and synthesis of the literature on diagnostic and
medication treatment disparities in African American children was presented. In total, 41 studies
published between 1999 and 2021 were included, with 38 cross-sectional studies, and three
longitudinal studies. Twenty-one of the included studies reported ADHD prevalence by race.
Within this sample of studies, ADHD prevalence was significantly lower in African American
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children compared to white children in 14 (66.7%) studies, while 5 studies (23.8%) reported no
significant difference, and 2 studies (9.5%) reported a significantly greater prevalence of ADHD
among African American children than White children. Regarding medication treatment
disparities, fifteen of 23 studies (65%) found that African American children with ADHD were
significantly less likely than White children with ADHD to be receiving a medication, while
eight (35%) found no significant difference between the groups. Treatment disparities were also
quantified in terms of medication adherence and discontinuation in three studies. Results of these
studies consistently reported treatment quality to be poorer among African American children
compared to White children.
Diagnostic and treatment disparity outcomes were analyzed for trends over time. Each
study’s reported odds for African American children either receiving a diagnosis of ADHD or
receiving a medication for ADHD were plotted against the year the data was collected. The
synthesis concluded that ADHD diagnostic disparities showed a trend toward reduction over
time, with the earliest data points grouped around an OR of 0.50 for ADHD diagnosis in African
American children, and final data points grouped around an OR of 0.90. The data points
clustered near the trend line. Conversely, medication treatment disparities did not follow the
same course. The treatment odds initially clustered around 0.50 and later around 0.75. The data
points were spread further from the trend line, indicating there was little association between
time and ADHD treatment disparities.
Very few studies assessed treatment quality, including medication selected, dosing,
formulation, or medication taking behaviors such as treatment duration, or alignment between
prescribed and actual dosing. Findings of the review were limited by the heterogeneity and bias
of methods in included studies and lack of culturally sensitive standardized tools for the
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assessment of ADHD. The review recommended that future research address the noted
limitations, further explore treatment quality, and describe within group variations to identify
factors contributing to MDM in African Americans.
The second manuscript provided a synthesis of the evidence on MDM in African
American caregivers of children with ADHD. Fourteen publications, comprising seven
observational, four qualitative, and three mixed method studies were included. The findings of
this review demonstrated that SDOHs as well as experiences of structural and cultural racism and
discrimination shaped the MDM beliefs and behaviors of African American caregivers of
children with ADHD. Three themes were found to influence MDM including fundamental
perspectives of ADHD, cultural norms for child behavior, and experiences of ADHD as a form
of social control.
The theme of fundamental perspectives of ADHD and cultural norms for childhood
behavior contained three subthemes: ADHD knowledge, ADHD explanatory model, and ADHD
cultural perceptions. ADHD knowledge pertained to the caregivers’ scientific knowledge of
ADHD. In general, African American caregivers reported less formal knowledge of ADHD, and
fewer contacts with individuals who had ADHD. An explanatory model refers to an individual’s
beliefs about an illness and its treatment, and the meaning attributed to that illness and treatment
(Kleinman, 1980). This review found that African American caregivers were less likely to
endorse medical or biological explanatory models for ADHD, and more likely to endorse
explanatory models related to parenting or nutrition. Finally, cultural perceptions related to
normal childhood behavior, especially an acceptance of hyperactivity in boys, was noted in
African American caregivers. In the second theme, each of the subthemes of fundamental
perspectives of ADHD and cultural norms for childhood behavior was connected to MDM.
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Caregivers with less formal ADHD knowledge, a non-biological explanatory model for ADHD,
or tolerance for hyperactivity were less likely to select medication treatment for ADHD. African
American caregivers expressed greater uncertainty in the efficacy of ADHD medications, and
greater concerns for side effects and addiction than White counterparts. Finally, African
American caregivers were unique in expressing concerns regarding ADHD as a form of social
control. This partially related to concerns for addiction and the historical introduction of illicit
substances in African American communities (Olaniyan et al., 2007). Additionally, the social
control theme encompassed experiences of the diagnosis and treatment of ADHD being used to
gain control over African American children at the behest of third parties (Olaniyan et al., 2007).
Recommendations for future research included further exploring how experiences of racism
contribute to ADHD treatment disparities and how these experiences can be addressed,
identification of barriers and facilitators to MDM, development of culturally sensitive ADHD
screening and diagnostic tools, investigation of within group variations, and exploration of MDM
as a process rather than an outcome.
The final manuscript presented a sequential exploratory mixed method study exploring
factors and testing their associations with MDM in low-income African American families of
children with ADHD. A preliminary qualitative case-study following Yin’s (2018) framework
was conducted in a sample of seven low-income African American caregivers of children with
ADHD recruited from an outpatient clinic in an urban New Jersey neighborhood. A total of
seven caregivers participated in six semi-structured interviews. Participants included mothers, a
step-father, and uncle of one child who was also the step-father of another child with ADHD, and
one grandmother. One step-father was interviewed concurrently with the child’s mother.
Interviews were analyzed as a whole, with line-by-line coding followed by second level coding
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and identification of themes. cross-case synthesis was conducted to identify themes across cases,
and discussion of codes and themes ensued until consensus was reached. Themes identified from
analysis of semi-structured interviews included child safety and volatility, caregiver aggravation,
caregiver mental health, sole caregiver status, school involvement, FCC and SDM.
In the second phase, a secondary analysis of data from the NSCH was conducted to test
the relationships proposed by the preliminary framework. The NSCH is a mail- or internet-based
survey conducted by the U.S. Census Bureau within the U.S. Department of Health and Human
Services covering the 50 states and the District of Columbia. The survey collects information on
key indicators of health and well-being for children ages 0-17. Data from the 2016-2019 surveys
were utilized. Qualitative themes were mapped to NSCH items that best operationalized the
theme. The investigators reviewed the themes, potential items, item scoring, and hypotheses until
there was agreement on item selection and scoring. The independent variables included
neighborhood safety, school safety, child volatility, an author derived safety and volatility
composite score, caregiver aggravation, caregiver mental health, family centered care (FCC),
shared-decision making (SDM), receipt of special education services, and contact by the school
for problems at school. The outcome variable was receipt of a medication for ADHD.
Additionally, demographic and descriptive variables included age, gender, insurance status
(uninsured or public insurance), and ADHD severity (mild, moderate, severe).
The Phase 2 sample included 450 African American children age 6-17with no insurance
or public insurance only who were diagnosed with ADHD. Univariate and logistic regression
analyses were conducted to identify relationships between independent variables and receipt of a
medication for ADHD. After accounting for ADHD severity, only previous receipt of special
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education services, and experiences of FCC and SDM were independently associated with
medication treatment.
Strengths. The breadth and depth of the initial manuscript provided a comprehensive
state of the science on ADHD disparities in African American children on which to base research
priorities. Resulting from findings of the first manuscript, the second manuscript uncovered gaps
in knowledge of how African American’s make decisions regarding the medical treatment of
ADHD in their children. The final manuscript had several strengths. First, it addressed gaps
identified by the first two manuscripts. Specifically, the qualitative phase of the study provided
an in-depth exploration of MDM in low-income African American caregivers of children with
ADHD. The level of detail provided by participants allowed for insights on ADHD treatment
disparities that had not previously been identified. Additionally, the second phase compared
MDM factors within low-income African American families. This is unlike the majority of
existing literature that compares all African American individuals to a White reference group.
Within group studies, such as this one, are essential to understanding heterogeneity within race,
and allow for the development of targeted interventions to address healthcare disparities
(Whitfield et al., 2008). For example, the significance of FCC and SDM to low-income
caregivers of children with ADHD had not previously been described. Finally, selecting a mixed
method design allowed for an inductive approach to an underexplored topic with subsequent
verification of findings. The Phase 2 sample was adequately powered and drawn from a national
database. Thus, the findings can be generalized to a broader population than if utilizing
qualitative methods alone.
Limitations. Constraints associated with data collection and investigator bias limit the
scope and validity of the exploratory phase of this study. Recruitment was prematurely
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concluded due to the coronavirus disease 2019 pandemic. Furthermore, the researcher was not
African American and not previously known to participants. Her status as an outsider may have
limited lines of inquiry, and restricted participant disclosure of information regarding their
experiences of MDM. The researcher’s bias may have influenced interpretation of data. Multiple
strategies were incorporated to limit bias including inclusion of multiple cases, cross-case
comparisons and confirmation with a second investigator (Yin, 2018). Despite these tactics, the
potential for bias to limit findings cannot be eliminated. Ultimately, data was insufficient to
generate a theory of MDM. However, there was adequate data from which to propose and test a
preliminary framework.
The use of secondary data analysis further limits the validity of findings. Information on
the response rate in the target population was not available. A low response rate may have biased
findings. Moreover, NSCH items selected were the best approximation of themes using
information available to test associations between themes and receipt of a medication for ADHD;
however, they were not an exact representation of desired information. Additionally, responses
relied on caregiver recall which may be inaccurate due to poor recall or stigma associated with
ADHD. Finally, the instrument may not have performed similarly across participants. Some
SDOH, such as neighborhood environment or social network, may have influenced participant
interpretation of items and responses, thus limiting the ability to identify differences between
participants.
Implications
Implications for Practice. The three manuscripts have several implications for practice.
The first manuscript indicates that despite more than twenty years of research describing inequity
in the treatment of ADHD for African American children, we have not responded sufficiently to
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address this disparity. The second manuscript reveals that some interventions to address
disparities may be simple. For example, given the low exposure to formal sources of ADHD
information or other individuals with ADHD, educational efforts in African American
communities, particularly if delivered by other community members, may be effective in
addressing knowledge gaps that contribute to treatment disparities. Conversely, other factors
may be more difficult to address. Both the second and third manuscript reveal the significance of
internalized racism to MDM. Concerns regarding addiction, social control, child safety, and
being dismissed by clinicians stem from experiences of living as African Americans. The main
finding of the third manuscript implies that the influence of these experiences on ADHD
treatment disparities can be overcome by clinicians and educators. Incorporating FCC and SDM
in clinician interactions with low-income families of children with ADHD will be essential to
achieving equity in ADHD outcomes. For example, clinicians should explore ADHD
explanatory models or expectations for childhood behavior with African American families, and
incorporate these factors into SDM for ADHD treatment. Interventions are required to address
the most common barriers to FCC and SDM amenable to clinician influence. These include lack
of time, lack of high quality culturally and developmentally appropriate family education
materials, and lack of clinician skill in eliminating power gradients and fostering SDM, trust, and
respect in interactions with children and their families (Boland et al., 2019). Finally, clinicians
must collectively and individually reflect on how we contribute to the ongoing disparities in
ADHD treatment and confront our biases in order to fully engage in FCC and SDM.
In the final manuscript, schools were also revealed as an important factor in ADHD
MDM. Schools can serve as a pipeline to the proper identification and treatment of ADHD in
low-income African American children. Programs offering training to educators, especially those
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working in special education, on recognition of ADHD symptoms and strategies to collaborate
with and support families of children with ADHD, as well as confronting unconscious bias are
key to promoting health equity. Likewise, developing partnerships between schools and
healthcare practices in underserved communities can address access barriers. School nurses can
play an invaluable role in acting as a bridge between the school and medical communities by
developing ongoing and deep relationships with African American families of children with
ADHD and advocating for their needs to external agencies, by screening for children who are not
adequately treated, and by building partnerships with community agencies to connect children
with services.
Implications for Education. Though concepts of SDM and FCC are not new to
healthcare, they have proved difficult to operationalize. Education is a starting point for
improved practice of SDM and FCC. Efforts to educate clinicians in FCC and SDM may be
effective in addressing barriers to implementation (Barr et al., 2014; Durand et al., 2018; Legare
et al., 2018). Concepts of FCC and SDM as well as practical application training should be
incorporated in both pre-licensure and continuing education for clinicians (Barr et al., 2014; Park
& Choi, 2020). Additionally, there is a need for patients to be prepared to participate in SDM
(Legare et al., 2018).
Recommendations for Future Research
Numerous studies are indicated based on the entirety of this dissertation. Findings from
the first manuscript suggest a need for similar investigations in other marginalized populations.
Many of the studies included also provided data on Hispanic children, and there have been
reviews of ADHD diagnostic and treatment disparities in this population (Eiraldi & Diaz, 2010).
However, information on disparities in other ethnicities, such as Asian, Native Hawaiian or other
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Pacific Islander, Native American, or Alaskan Native, is absent. Also, there is a need to measure
disparities in treatment quality rather than focusing on treatment prevalence. In children who
have been prescribed a medication or ADHD, large surveys such as the NSCH should measure
additional items including prescribed medication name, dose, frequency, formulation, and
duration of treatment. Additionally, medication taking behaviors should be better described
including how often the medication is taken as prescribed, how medication taking varies from
the prescribed regimen, and root causes of discrepancies between medication taking and the
prescribed regimen. Finally, ADHD medication treatment may require trial and error for
optimization of efficacy and minimization of side effects (Wolraich. et al., 2019). Patients may
expect trials with different medications as well as dosage titrations before arriving at the ideal
regimen. Research is needed to explore if and how the medication initiation process contributes
to disparities.
The second manuscript revealed that investigation of how experiences of racism and
discrimination, or internalized racism (Williams et al., 2019) contribute to MDM in African
American caregivers of children with ADHD is necessary. The third manuscript offered insights
to this end; however, a single study cannot fully address this gap in the literature. There is also a
need to explicate the process of MDM. This can be accomplished through qualitative research,
specifically a grounded theory study aimed at delineating the process of MDM in African
American caregivers of children with ADHD. The third manuscript was an initial step in this
direction, but does not provide a complete understanding of African American caregiver
experiences, or MDM as a process. The third manuscript also illuminates additional areas for
future research. A large body of research exists evaluating interventions for increasing SDM and
FCC however, the efficacy of these interventions is uncertain (Legare et al., 2018; Park et al.,
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2018). Further, there is an absence of studies evaluating the impact of SDM on equity (Legare et
al., 2018). The findings of the current study underscore the importance of conducing high quality
studies to identify interventions promoting FCC and SDM, and evaluate their efficacy in
achieving health equity for children with ADHD.
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